UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(D)
OF THE SECURITIES AND EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): March 9, 2015
HANSEN MEDICAL, INC.
(Exact name of registrant as specified in charter)
|
|
|
|
|
Delaware |
|
001-33151 |
|
14-1850535 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
800 East Middlefield Road
Mountain View, California 94043
(Address of principal executive offices and zip code)
Registrants telephone number, including area code: (650) 404-5800
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01. |
Entry into a Material Definitive Agreement. |
On March 11, 2015, Hansen Medical,
Inc. (the Company) completed a private placement transaction (the Investment) pursuant to the terms of a securities purchase agreement, dated March 9, 2015 (the Purchase Agreement), by and among the Company
and certain existing stockholders of the Company (the Purchasers). At the closing of the Investment, the Company (i) issued and sold 53,846 shares of Series A Convertible Participating Preferred Stock, par value $0.0001 per share
(the Preferred Stock), at a per share price of $650.00 and (ii) issued warrants (the Warrants) to purchase an aggregate of 53,846,000 shares (the Warrant Shares) of the Companys common stock, par value
$0.0001 per share (the Common Stock), for an aggregate purchase price of $35.0 million.
As promptly as practicable following
the date of the Purchase Agreement, the Company is required to hold a meeting of its stockholders in order to, among other things, vote upon the approval of: (i) an increase in the amount of the Companys authorized Common Stock,
(ii) the taking of any and all corporate actions in furtherance of fully effectuating the full conversion of the Preferred Stock and the full exercise of the Warrants and certain other warrants, including the issuance of additional Common Stock
and the correction or removal of any limitations restricting the foregoing conversion and exercise, and (iii) the removal of the restriction prohibiting the exercise of certain Warrants and certain other warrants if, after giving effect to such
exercise, the holder of such Warrants and certain other warrants would beneficially own in excess of 19.99% of the outstanding shares of Common Stock (collectively, the Requisite Stockholder Approval).
The Preferred Stock will be convertible into shares of Common Stock, upon the election of at least a majority of the then outstanding shares
of Preferred Stock, only to the extent that such conversion does not trigger a shareholder approval requirement in accordance with NASDAQ listing rules, and thereafter automatically upon obtaining the Requisite Stockholder Approval. The number of
shares of Common Stock into which each share of Preferred Stock is convertible is equal to the number obtained by dividing (i) the sum of $650.00 and the amount of any accrued but unpaid dividends thereon by (ii) the lesser of $0.65 and
the per share trailing volume-weighted average share price of the Common Stock on NASDAQ for the ten trading days ending on the date prior to such conversion, subject to customary anti-dilution adjustments. Prior to conversion, the Preferred Stock
will bear interest at an initial rate of 2%, which interest rate will increase by 2% quarterly. The Warrants are comprised of one tranche of Series E Warrants with an exercise price of the lesser of $0.975 per share or a 50% premium on the per share
trailing volume-weighted average share price of the Common Stock on NASDAQ for the ten trading days ending on the date prior to the date on which the Requisite Stockholder Approval is obtained (or, if such approval is not necessary, the earlier of
the date on which such Warrant is exercised or December 31, 2015), subject to customary anti-dilution adjustments. The Warrants have an exercise period of two years from the date of issuance.
The Purchasers include entities affiliated with Oracle Partners, LP (the Oracle Entities), the Schuler Family Foundation and the
Frederic Hutchins Moll Revocable Trust. The Oracle Entities, Jack Schuler and the Schuler Family Foundation and Fred Moll and the Frederic Hutchins Moll Revocable Trust are existing stockholders of the Company. Jack Schuler is a member of the Board
of Directors of the Company. Fred Moll is the founder of the Company.
The Purchase Agreement contains representations, warranties and
covenants of the Company and the respective Purchasers. The representations, warranties and covenants contained in the Purchase Agreement may be subject to limitations agreed upon by the contracting parties, including being qualified by disclosures
exchanged between the parties in connection with the execution of the Purchase Agreement. The representations and warranties may have been made for the purposes of allocating contractual risk between the parties to the Purchase Agreement instead of
establishing these matters as facts.
The Preferred Stock and Warrants issued pursuant to the Purchase Agreement have not been registered
under the Securities Act of 1933, as amended (the Act), and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The Company is relying on the private placement
exemption from registration provided by Section 4(a)(2) of the Act and by Rule 506 of Regulation D, promulgated by the Securities and Exchange Commission (the SEC).
In connection with the closing of the Investment, on March 11, 2015, the Company entered into an amendment and restatement to the Amended
and Restated Investor Rights Agreement, dated August 11, 2014, by and among the Company and the purchasers named therein (the Second Amended and Restated IRA). Pursuant to the Second Amended and Restated IRA, the Company agreed to
file a registration statement on Form S-3 with the SEC covering resales of the Common Stock into which the Preferred Stock is convertible (the Convertible Shares) and the Warrant Shares promptly following the Requisite Stockholder
Approval and to use its reasonable best efforts to cause the registration statement to become effective as soon as practicable. In the event the registration statement covering resales of the Convertible Shares and Warrant Shares is not filed or
declared effective by the applicable dates, the parties to the Second Amended and Restated IRA are entitled to specific performance. The Company is generally required to maintain the effectiveness of the registration statement until the date that is
the later of (i) two years from the closing of the Investment, (ii) the date by which all the Convertible Shares and Warrant Shares may be sold without volume or manner of sale restrictions which may be applicable to affiliates under Rule
144 under the Act or (iii) the date on which all of the Convertible Shares and Warrant Shares are sold. The Company shall bear all expenses of such registration of the Convertible Shares and Warrant Shares.
The foregoing descriptions of the Investment, the Purchase Agreement, the Second Amended and
Restated IRA, the Preferred Stock and the Warrants do not purport to be complete and are qualified in their entirety by reference to the complete text of such documents, copies of which are filed as exhibits hereto.
Item 3.02. |
Unregistered Sales of Equity Securities. |
The disclosure set forth above Item 1.01
is incorporated herein for this Item 3.02.
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits
The following is a list of the exhibits filed herewith.
|
|
|
Exhibit No. |
|
Description of Exhibit |
|
|
3.1 |
|
Certificate of Designations, Preferences and Rights of Series A Convertible Participating Preferred Stock |
|
|
4.1 |
|
Securities Purchase Agreement, dated March 9, 2015, by and among the Company and the Purchasers named therein |
|
|
4.2 |
|
Form of Series E Warrant |
|
|
4.3 |
|
Second Amended and Restated Investor Rights Agreement, dated March 11, 2015, by and among the Company and the Purchasers named therein |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
HANSEN MEDICAL, INC.
(Registrant) |
|
|
|
|
Date: March 12, 2015 |
|
|
|
|
|
/s/ Christopher P. Lowe |
|
|
|
|
|
|
Christopher P. Lowe |
|
|
|
|
|
|
Interim Chief Financial Officer |
EXHIBIT INDEX
|
|
|
Exhibit No. |
|
Description of Exhibit |
|
|
3.1 |
|
Certificate of Designations, Preferences and Rights of Series A Convertible Participating Preferred Stock |
|
|
4.1 |
|
Securities Purchase Agreement, dated March 9, 2015, by and among the Company and the Purchasers named therein |
|
|
4.2 |
|
Form of Series E Warrant |
|
|
4.3 |
|
Second Amended and Restated Investor Rights Agreement, dated March 11, 2015, by and among the Company and the Purchasers named therein |
Exhibit 3.1
Execution Version
CERTIFICATE OF DESIGNATIONS, PREFERENCES
AND RIGHTS OF
SERIES A
CONVERTIBLE PARTICIPATING
PREFERRED STOCK
OF
HANSEN MEDICAL, INC.
(Pursuant to Section 151 of the
Delaware General Corporation Law)
Hansen Medical, Inc., a Delaware corporation (the Corporation), hereby certifies that the following resolution was duly
approved and adopted by the Board of Directors of the Corporation (the Board of Directors) at a meeting of the Board of Directors, which resolution remains in full force and effect on the date hereof:
RESOLVED, that pursuant to the authority expressly granted to and vested in the Board of Directors by the provisions of the Amended and
Restated Certificate of Incorporation of the Corporation, as further amended to date (the Certificate of Incorporation), and the Amended and Restated Bylaws of the Corporation (the Bylaws), and in accordance
with Section 151 of the General Corporation Law of the State of Delaware (the DGCL), there is hereby created, out of the 10,000,000 shares of Preferred Stock, par value $.0001 per share (the Preferred
Stock), of the Corporation remaining authorized, unissued and undesignated, a series of the Preferred Stock consisting of 100,000 shares, which series shall have the following powers, designations, preferences and relative, participating,
optional or other rights, and the following qualifications, limitations and restrictions (in addition to any powers, designations, preferences and relative, participating, optional or other rights, and any qualifications, limitations and
restrictions, set forth in the Certificate of Incorporation that are applicable to the Preferred Stock):
SECTION 1 Designation of
Amount.
(a) 100,000 shares of Preferred Stock shall be, and hereby are, designated the Series A Convertible Participating
Preferred Stock (the Series A Preferred Stock), par value $.0001 per share.
(b) Subject to the requirements of
the DGCL, the Certificate of Incorporation and this Certificate of Designations, the number of shares of Preferred Stock that are designated as Series A Preferred Stock may be increased or decreased by vote of the Board of Directors;
provided, that no decrease shall reduce the number of shares of Series A Preferred Stock to a number less than the number of such shares then outstanding plus the number of such shares that may be issued as dividends on the Series A
Preferred Stock then outstanding and such additional shares issued as dividends. Any shares of Series A Preferred Stock converted, redeemed, purchased or otherwise acquired by the Corporation in any manner whatsoever shall, automatically and without
further action, be retired and canceled promptly after the acquisition thereof, and shall become authorized but unissued shares of Preferred Stock when the Corporation shall take such action as may be necessary to reduce the number of authorized
shares of the Series A Preferred Stock and may be reissued as part of a new series of any class or series of Preferred Stock in accordance with the Certificate of Incorporation and this Certificate of Designations.
SECTION 2 Certain Definitions.
Unless the context otherwise requires, the terms defined in this Section 2 shall have, for all purposes of this resolution, the
meanings specified (with terms defined in the singular having comparable meanings when used in the plural).
Affiliate
means any person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a person, as such terms are used in and construed under Rule 405 under the Securities Act.
Board of Directors shall have the meaning set forth in the preamble to this Certificate of Designations.
Bylaws shall have the meaning set forth in the preamble to this Certificate of Designations.
Certificate of Incorporation shall have the meaning set forth in the preamble to this Certificate of Designations.
Common Stock shall mean the common stock, par value $0.0001 per share, of the Corporation.
Conversion Date shall have the meaning ascribed to such term in Section 6(e).
Conversion Price shall mean the lesser of (a) $0.65 and (b) the per share trailing volume-weighted average share
price of the Common Stock on Nasdaq for the ten (10) trading days ending on the date prior to the date on which the Requisite Stockholder Approval is obtained (or, if such approval is not necessary, on the Conversion Date), in each case,
subject to adjustment from time to time in accordance with Section 6(d).
Corporation shall have the
meaning set forth in the preamble to this Certificate of Designations.
Counter Proposal shall have the meaning set
forth in Section 8(b).
Current Market Price shall mean the higher of (a) the per share trailing
volume-weighted average share price of the Common Stock on Nasdaq for the twenty (20) previous trading days and (b) the closing share price of the Common Stock on Nasdaq for the previous day.
Deemed Liquidation shall mean a consolidation or merger of the Corporation with or into any other person or persons, a
statutory share exchange, the sale of all or substantially all of the Corporations assets or the sale of capital stock in one or more related transactions wherein the shareholders of the Corporation immediately prior to the effectiveness of
such transaction or transactions hold less than 50% of the capital stock of the Corporation or the surviving entity immediately after such transaction.
Dividend Period shall have the meaning ascribed to such term in Section 4(a)(i).
DGCL shall have the meaning set forth in the preamble to this Certificate of Designations.
Excluded Securities shall mean:
-2-
(i) shares of Common Stock issued (or issuable upon exercise of rights, options or warrants
outstanding from time to time) or granted to (A) officers, directors or employees of, or consultants to, the Corporation pursuant to a stock bonus, stock option plan, employee stock purchase plan, restricted stock plan or other similar plan or
agreement or otherwise or (B) persons or entities with whom the Corporation has business relationships, including under equipment leasing arrangements, bank or other institutional loans, acquisitions of companies or product lines or other
arrangements or transactions wherein the principal purpose of the issuance of such shares (or rights, warrants or options) is for non-equity financing purposes; provided, that, with respect to clauses (A) and (B) such grants
or issuances are approved by the Board of Directors and any shares of Common Stock issued or issuable in such transactions (including as a result of the exercise or conversion of any rights, options or warrants issued in connection therewith) after
the Initial Issue Date do not exceed in the aggregate, when combined with all other securities then outstanding that were issued in compliance with this clause (i) after the Initial Issue Date, 3% of the outstanding shares of Common Stock on a
fully diluted basis on the Initial Issue Date;
(ii) shares of Common Stock issued or issuable as a result of any stock split,
combination, dividend, distribution, reclassification, exchange or substitution for which an equitable adjustment is provided for in Section 6(d);
(iii) shares of Common Stock issued in the Rights Offering; and
(iv) shares of Common Stock issuable upon exercise of rights, options, warrants, notes or other rights to acquire securities of the
Corporation outstanding as of the Initial Issue Date, including the Series E Warrants issued pursuant to the Stock Purchase Agreement.
Existing Credit Agreement shall mean that certain Amended and Restated Loan and Security Agreement, dated as of
August 23, 2013, by and among the Corporation, the entities from time to time party thereto as Lenders and White Oak Global Advisors, LLC.
Fair Market Value shall mean, with respect to any listed security, its Market Price, and with respect to any property or
assets other than cash or listed securities, the fair value thereof determined in good faith by the Board of Directors.
Initial
Dividend Rate shall have the meaning set forth in Section 4(a)(i).
Initial Issue Date shall mean
the date that shares of Series A Preferred Stock are first issued by the Corporation.
Junior Securities shall have the
meaning set forth in Section 9(c).
LIBOR shall mean the daily rate of interest as published in the Money
Rates section of The Wall Street Journal as London Interbank Offered Rates (Libor) with a term of three (3) months. If The Wall Street Journal ceases to publish the London Interbank Offered Rates (Libor), the Corporation may select a substitute
publication or service that publishes the London Interbank Offered Rates (Libor), or its equivalent.
Liquidation shall
have the meaning ascribed to such term in Section 5(a).
Market Price shall mean, as to any class of listed
securities, the average of the closing prices of such securitys sales on all United States securities exchanges on which such security may at the time be listed, or, if there have been no sales on any such exchange on any day, the
-3-
average of the highest bid and lowest asked prices on all such exchanges at the end of such day, or, if on any day such security is not so listed, the average of the representative bid and asked
prices quoted by the Nasdaq Stock Market LLC (Nasdaq) or a major non-U.S. exchange, but not on the basis of pink sheets, as of 4:00 P.M., New York time, on such day or any successor organization, in each such case averaged
over a period of twenty-one (21) days consisting of the day (or if such day is not a trading day, the immediately preceding trading day) as of which Market Price is being determined and the twenty (20) consecutive trading days
prior to such day.
New Securities shall mean, collectively, equity or debt securities of the Corporation or any of its
Subsidiaries, whether or not currently authorized, as well as rights, options, or warrants to purchase equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity
securities.
Offer Notice shall have the meaning set forth in Section 8(a).
Parity Securities shall have the meaning set forth in Section 9(b).
Participating Dividends shall have the meaning ascribed to such term in Section 4(b).
person shall mean any individual, partnership, company, limited liability company, joint venture, association, joint-stock company, trust, unincorporated organization, government or agency or political subdivision thereof, or other entity.
Preferred Stock shall have the meaning set forth in the preamble to this Certificate of Designations.
Redemption Date shall have the meaning ascribed to such term in Section 7(b).
Redemption Price shall have the meaning ascribed to such term in Section 7(a).
Regular Dividend Payment Date shall have the meaning ascribed to such term in Section 4(a)(i).
Regular Dividends shall have the meaning ascribed to such term in Section 4(a)(i).
Requisite Holders shall mean the holders of at least a majority of the then outstanding shares of Series A Preferred Stock.
Requisite Stockholder Approval shall have the meaning ascribed to it in the Securities Purchase Agreement.
Rights Offering shall have the meaning ascribed to it in the Securities Purchase Agreement.
Securities Act shall mean the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
Securities Purchase Agreement shall mean the Securities Purchase Agreement dated as the date hereof, by and among the
Corporation and the purchasers identified on Exhibit A thereto.
Senior Securities shall have the meaning set forth in
Section 9(a).
Series A Preferred Stock shall have the meaning set forth in Section 1(a).
-4-
Series A Recapitalization Event shall mean any stock dividend, stock split,
combination, reorganization, recapitalization, reclassification, or other similar event involving a change in the capital structure of the Series A Preferred Stock.
Series A Stockholder shall have the meaning set forth in Section 8.
Series E Warrants shall have the meaning ascribed to it in the Securities Purchase Agreement.
Stated Value shall mean the per share stated value for a share of Series A Preferred Stock of $650.00.
subsidiary means, with respect to any person, (a) a company a majority of whose capital stock with voting power, under
ordinary circumstances, to elect directors is at the time, directly or indirectly, owned by such person, by a subsidiary of such person, or by such person and one or more subsidiaries of such person, (b) a partnership in which such person or a
subsidiary of such person is, at the date of determination, a general partner of such partnership, or (c) any other person (other than a company) in which such person, a subsidiary of such person or such person and one or more subsidiaries of
such person, directly or indirectly, at the date of determination thereof, has (i) at least a majority ownership interest, (ii) the power to elect or direct the election of the directors or other governing body of such person, or
(iii) the power to direct or cause the direction of the affairs or management of such person. For purposes of this definition, a person is deemed to own any capital stock or other ownership interest if such person has the right to acquire such
capital stock or other ownership interest, whether through the exercise of any purchase option, conversion privilege or similar right.
Subsidiary shall mean a subsidiary of the Corporation.
SECTION 3 Voting Rights.
(a) General. Except as otherwise provided by the DGCL, other applicable law or as provided in this Certificate of
Designations, the holders of Series A Preferred Stock shall not be entitled to vote (or render written consents) on any matter submitted for a vote of (or written consents in lieu of a vote as permitted by the DGCL, the Certificate of Incorporation
and the Bylaws) holders of Common Stock.
(b) Protective Provisions. The Corporation shall not, and shall not permit any of its
Subsidiaries to, directly or indirectly, without the affirmative vote (or written consent as permitted by the DGCL, the Certificate of Incorporation and Bylaws) of the Requisite Holders, voting (or consenting) as a separate class:
(i) amend, alter, modify or repeal (whether by merger, consolidation or otherwise) this Certificate of Designations, the Certificate of
Incorporation or the Bylaws in any manner that adversely affects the rights, preferences, privileges or the restrictions provided for the benefit of, the Series A Preferred Stock (in each case, including without limitation, changing the total number
of Series A Preferred Stock that the Corporation shall have the authority to issue);
(ii) reclassify, alter or amend any securities of
the Corporation or any Subsidiary in a manner that adversely affects the designations, preferences, powers and/or the relative participating, optional or other special rights, or the restrictions provided for the benefit of the Series A Preferred
Stock;
-5-
(iii) in any manner authorize, create, designate, issue or sell any (A) class or series of
capital stock (including shares of treasury stock) that would be classified as Senior Securities or Parity Securities or (B) rights, options, warrants or other securities (including debt securities) convertible into or exercisable or
exchangeable for capital stock or any equity security or having any other equity feature, in each case, that would be classified as either Senior Securities or Parity Securities, except as may be necessary in connection with the declaration and
payment of in-kind dividends to holders of outstanding shares of Series A Preferred Stock;
(iv) modify in any material way the business
of the Corporation or any of its Subsidiaries, including entering into a new line of business;
(v) acquire or cause a Subsidiary to
acquire, in any transaction or series of related transactions, the stock, business or material assets of any person or any business or assets of any person (in any such case, whether through the acquisition of securities, assets, or otherwise) where
the consideration payable by the Corporation and or its Subsidiaries in connection with such acquisition (including any contingent or potential consideration), when taken together with all other consideration payable or paid by the Corporation
and/or any of its Subsidiaries in connection with all other acquisitions (including contingent or potential consideration) by the Corporation and/or its Subsidiaries in the twelve (12) month period preceding the closing date of such
acquisition, exceeds $1,000,000;
(vi) sell, transfer, license, assign, lease mortgage, pledge, grant a security interest in or otherwise
dispose of or encumber, in any transaction or series of related transactions, any capital stock or assets of the Corporation or any Subsidiary, outside the ordinary course of business (other than pursuant to the Existing Credit Agreement);
(vii) repay, repurchase or redeem any indebtedness except as required pursuant to the terms of such indebtedness;
(viii) adopt a shareholders rights plan, or other anti-takeover plan or device;
(ix) effect a Liquidation or Deemed Liquidation;
(x) hire, terminate, increase the salary of or modify any other material employment terms of any member of senior management of the
Corporation;
(xi) incur or suffer to exist at any time, or permit the Corporation or any of the Corporations Subsidiaries to incur
or suffer to exist at any time, any indebtedness in excess of $1,000,000, other than indebtedness pursuant to the Existing Credit Agreement or any refinancing thereof in the same amount or less;
(xii) enter into, or become subject to, any agreement or instrument or other obligation which by its terms restricts the Corporations
ability to perform its obligations under this Certificate of Designation, including the ability of the Corporation to pay dividends or make any redemption or other liquidation payment required hereunder (except for the Existing Credit Agreement);
(xiii) purchase or redeem (or permit any subsidiary to purchase or redeem) or pay or declare any dividend, or make any distribution on,
any shares of capital stock of the Corporation, other than redemptions of or dividends or distributions on the Series A Preferred Stock as expressly authorized herein; or
-6-
(xiv) enter into any agreement to do any of the foregoing that is not expressly made conditional
on obtaining the affirmative vote or written consent of the Requisite Holders.
SECTION 4 Dividends.
(a) Dividend Amount.
(i) Regular Dividends. In addition to any Participating Dividends (as described below) to which holders of Series A Preferred Stock may
be entitled, the holders of the outstanding shares of Series A Preferred Stock shall be entitled to receive, for each share of Series A Preferred Stock, cumulative quarterly dividends at the quarterly rate that shall initially be 2.0% (the
Initial Dividend Rate) of the sum of (A) the Stated Value plus (B) all accrued and unpaid Regular Dividends on such share of Series A Preferred Stock as of the first day of the applicable Dividend Period, in each case as
adjusted for any stock dividends, splits, combinations and similar events (the Regular Dividends). Regular Dividends are payable in additional shares of Series A Preferred Stock. Regular Dividends will accrue on a daily basis and
will be cumulative from the date of issuance and are payable quarterly in arrears on the last day of each of June, September, December and March (each such day, a Regular Dividend Payment Date), or, if such date is not a business
day, the succeeding business day. The first Dividend Period begins on, and includes, the Initial Issue Date and ends on, and includes the next succeeding Regular Dividend Payment Date, and each subsequent Dividend Period begins
on, and includes, the day after a Regular Dividend Payment Date and ends on, and includes, the next succeeding Regular Dividend Payment Date. The Initial Dividend Rate will increase by 2.0% on each Regular Dividend Payment Date (e.g., to 4.0% on the
first Regular Payment Date, etc.) for so long as the Series A Preferred Stock remains outstanding. The amount of Regular Dividends payable for the initial dividend period, or any other dividend period shorter or longer than a full quarterly dividend
period, will be computed on the basis of a quarter consisting of three 30-day months. Regular Dividends will be paid to the holders of record of Series A Preferred Stock as they appear in the records of the Corporation at the close of business on
the 15th day of the calendar month in which the applicable Regular Dividend Payment Date falls or on such other date designated by the Board of Directors for the payment of Regular Dividends that is not more than sixty (60) days or less than
ten (10) days prior to such Regular Dividend Payment Date. Any payment of a Regular Dividend will first be credited against the earliest accumulated but unpaid Regular Dividend due with respect to such share that remains payable.
(b) Participating Dividends. If the Board of Directors shall declare a dividend or other distribution payable upon the then outstanding
shares of Common Stock, whether in cash, in kind or in other securities or property, the holders of the outstanding shares of Series A Preferred Stock shall be entitled to the amount of dividends as would be payable in respect of the number of
shares of Common Stock into which the shares of Series A Preferred Stock held by each holder thereof could be converted, without regard to any restrictions on conversion, in accordance with the provisions of Section 6 hereof, such number
to be determined as of the record date for determination of holders of Common Stock entitled to receive such dividend or, if no such record date is established, as of the date of such dividend (Participating Dividends).
Participating Dividends are payable at the same time as and when dividends on the Common Stock are paid to the holders of Common Stock.
(c) Prior to declaring any dividend or making any distribution on or with respect to the shares of Series A Preferred Stock, the Corporation
shall take all actions necessary or advisable under the DGCL to permit the payment of Regular Dividends and Participating Dividends to the holders of Series A Preferred Stock.
-7-
SECTION 5 Liquidation Preference.
(a) Liquidation Preference of Series A Preferred Stock. Subject to Section 5(b) below, in the event of any liquidation,
dissolution, or winding up of the Corporation whether voluntary or involuntary, or in the event of its insolvency (a Liquidation), the holders of Series A Preferred Stock shall be entitled to have set apart for them, or to be
paid, out of the assets of the Corporation available for distribution to stockholders (whether such assets are capital, surplus or earnings) after provision for payment of all debts and liabilities of the Corporation in accordance with the DGCL,
before any distribution or payment is made with respect to any shares of Junior Securities and subject to the liquidation rights and preferences of any class or series of Senior Securities and Parity Securities, an amount equal to the greater of
(i) the Stated Value per share of Series A Preferred Stock (which amount shall be subject to an equitable adjustment in the event of any Series A Recapitalization Event) plus the amount of all accrued and unpaid Regular Dividends
thereon, whether or not declared, up to and including the date full payment shall be tendered to the holders of the Series A Preferred Stock with respect to such Liquidation and (ii) such amount as would have been payable on the number of
shares of Common Stock into which the shares of Series A Preferred Stock held by each holder thereof could have been converted immediately prior to such Liquidation in accordance with the provisions of Section 6 hereof.
(b) Deemed Liquidation. In the event of a Deemed Liquidation, the holders of Series A Preferred Stock shall be entitled to have set
apart for them, or to be paid, out of the assets of the Corporation available for distribution to stockholders (whether such assets are capital, surplus or earnings) after provision for payment of all debts and liabilities of the Corporation in
accordance with the DGCL, before any distribution or payment is made with respect to any shares of Junior Securities and subject to the liquidation rights and preferences of any class or series of Senior Securities and Parity Securities, an amount
equal to the greater of (i) 200% of the sum of (A) the Stated Value per share of Series A Preferred Stock (which amount shall be subject to an equitable adjustment in the event of any Series A Recapitalization Event) plus
(B) the amount of all accrued and unpaid Regular Dividends thereon, whether or not declared, up to and including the date full payment shall be tendered to the holders of the Series A Preferred Stock with respect to such Liquidation and
(ii) such amount as would have been payable on the number of shares of Common Stock into which the shares of Series A Preferred Stock held by each holder thereof could have been converted immediately prior to such Liquidation in accordance with
the provisions of Section 6 hereto.
(c) Insufficient Assets. If, upon any Liquidation or Deemed Liquidation, the
assets legally available for distribution among the holders of the Series A Preferred Stock and any Parity Securities of the Corporation shall be insufficient to permit payment to such holders of the full preferential amounts as provided for in
Section 5(a) above, then such holders shall share ratably in any distribution of available assets according to the respective amounts which would otherwise be payable with respect to the securities held by them upon such liquidating
distribution if all amounts payable on or with respect to such securities were paid in full, based upon the aggregate liquidation value payable upon all shares of Series A Preferred Stock and any Parity Securities then outstanding.
-8-
(d) Distribution to Junior Securities. After such payment shall have been made in full to
the holders of the Series A Preferred Stock, or funds necessary for such payment shall have been set aside by the Corporation in trust for the account of holders of the Series A Preferred Stock so as to be available for such payment, the remaining
assets available for distribution shall be distributed ratably among the holders of the Junior Securities in accordance with the terms of such securities.
(e) Distributions Other than Cash. Whenever the distribution provided for in this Section 5 shall be payable in property
other than cash, the value of such distribution shall be the Fair Market Value thereof. All distributions (including distributions other than cash) made hereunder shall be made pro rata to the holders of Series A Preferred Stock.
(f) Equitable Adjustments. The amounts to be paid or set aside for payment as provided above in this Section 5 shall be
proportionately increased or decreased in inverse relation to the change in the number of outstanding shares resulting from any Series A Recapitalization Event.
SECTION 6 Conversion Rights.
(a) General. Subject to and upon compliance with the provisions of this Section 6, to the extent that such conversions do
not trigger a shareholder approval requirement in accordance with Nasdaq listing rules, prior to the Requisite Stockholder Approval, upon the election of the Requisite Holders, each holder of shares of Series A Preferred Stock shall be entitled, at
its option, at any time and from time to time, to convert all or any such shares of Series A Preferred Stock into the number of fully paid and nonassessable shares of Common Stock equal to the number obtained by dividing (i) the Stated Value of
such Series A Preferred Stock, plus the amount of any accrued but unpaid Regular Dividends as of the Conversion Date by (ii) the Conversion Price in effect on the Conversion Date (determined as provided in this Section 6).
(b) Automatic Conversion. Upon the Requisite Stockholder Approval, all shares of Series A Preferred Stock shall be automatically
converted into the number of shares of Common Stock into which such shares of Series A Preferred Stock are then convertible in accordance with Section 6(a) without any further action by the holders of such shares and whether or not the
certificates representing such shares are surrendered to the Corporation or its transfer agent.
(c) Fractions of Shares.
Fractional shares may not be issued in connection with any conversion. If any fractional interest in a share would be deliverable upon conversion, such fractional share shall be rounded up to the next whole number.
(d) Adjustments to Conversion Price.
(i) If the Corporation shall, at any time or from time to time after the Initial Issue Date, issue Additional Shares of Common Stock, without
consideration or for consideration per share less than the Current Market Price in effect immediately prior to the announcement date for such issuance, then the Conversion Price shall forthwith be lowered (but in no event increased) to a price equal
to amount determined by multiplying such Conversion Price by a fraction:
(A) the numerator of which shall be (1) the
number of shares of Common Stock outstanding immediately prior to the announcement date for such issuance of such Additional Shares of Common Stock (calculated on a fully-diluted basis assuming the exercise or conversion of all Options or
Convertible Securities) plus (2) the number of shares of Common Stock which the gross aggregate consideration, if any,
-9-
received by the Corporation for the total number of such Additional Shares of Common Stock so issued would purchase at the Current Market Price in effect immediately prior to the announcement
date for such issuance, and
(B) the denominator of which shall be (1) the number of shares of Common Stock
outstanding immediately prior to the issuance of such Additional Shares of Common Stock (calculated on a fully-diluted basis assuming the exercise or conversion of all Options or Convertible Securities) plus (2) the number of such
Additional Shares of Common Stock so issued.
Any such adjustment shall become effective immediately upon issuance of such Additional Shares of Common
Stock.
(ii) For the purposes of any adjustment of a Conversion Price pursuant to this Section 6(d), the following definitions
shall be applicable:
(A) Option shall mean rights, options or warrants to subscribe for, purchase or
otherwise acquire Common Stock or Convertible Securities.
(B) Convertible Securities shall mean any
evidences of indebtedness, shares or other securities directly or indirectly convertible into or exchangeable for Common Stock other than the Series A Preferred Stock.
(C) Additional Shares of Common Stock shall mean all shares of Common Stock issued (or, pursuant to
subsection 6(d)(iii) below, deemed to be issued) by the Corporation after the Initial Issue Date, other than shares of Excluded Securities or Common Stock issued or issuable:
(1) as a dividend or distribution on the Series A Preferred Stock;
(2) upon conversion of shares of Series A Preferred Stock; or
(3) pursuant to the Excluded Securities to the extent such shares were previously taken into account for purposes of the limitation in the
definition of Excluded Securities;
(D) Rights or Rights to Acquire Common Stock
shall mean all rights issued by the Corporation to acquire Common Stock whether by exercise of a warrant, option or similar call, or conversion of any existing instruments, in either case for consideration fixed, in amount or by formula, as of the
date of issuance other than those rights described in subclauses (1) through (3) of clause (C) above.
(iii) Deemed
Issuances. If the Corporation at any time or from time to time after the Initial Issue Date issues any Options or Convertible Securities or Rights to Acquire Common Stock, then the maximum number of shares of Common Stock (as set forth in the
instrument relating thereto without regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or Rights to Acquire Common Stock or, in the case of Convertible Securities,
issuable upon the conversion or exchange of such Convertible Securities, in each case, as of the date of their issuance, shall be deemed to be the number of Additional Shares of Common Stock issued as of the time of such issue; provided that
Additional Shares of Common Stock shall not be deemed to have been
-10-
issued unless the consideration per share (determined pursuant to subsection 6(d)(v) hereof) that would be received by the Corporation for such Additional Shares of Common Stock upon such
exercise, conversion or exchange would be less than the Current Market Price in effect immediately prior to such issuance, and provided, further, that in any such case:
(A) no further adjustment in the Conversion Price shall be made upon the subsequent issuance of shares of Common Stock upon the
exercise of such Options or Rights to Acquire Common Stock or upon the conversion or exchange of such Convertible Securities;
(B) upon the expiration or termination of any unexercised Option, Right to Acquire Common Stock or Convertible Security, the
Conversion Price shall be adjusted immediately to reflect the applicable Conversion Price which would have been in effect had such Option, Right to Acquire Common Stock or Convertible Security (to the extent outstanding immediately prior to such
expiration or termination) never been issued;
(C) if with respect to any Option, Right to Acquire Common Stock or
Convertible Security, there shall have been an increase or decrease, with the passage of time or otherwise, in the consideration (determined pursuant to subsection 6(d)(v) below) payable upon the exercise, conversion or exchange thereof, then the
Conversion Price then in effect shall be readjusted by (x) treating the Additional Shares of Common Stock, if any, actually issued or issuable pursuant to the exercise of such Option, Right to Acquire Common Stock or Convertible Security as
having been issued or issuable for the consideration actually received and receivable therefor and (y) treating any Option, Right to Acquire Common Stock or Convertible Security which remains outstanding as being subject to exercise, conversion
or exchange on the basis of such revised consideration payable as shall be in effect at such time; provided that no such adjustment need be made to the extent that the event giving rise to the adjustment referred to in this paragraph
gives rise to an adjustment to the Conversion Price that is covered by another provision of this Section 6(d); and
(D) in the event of any change in the number of shares of Common Stock issuable upon the exercise, conversion or exchange of
any Option, Right or Convertible Security, including a change resulting from the anti-dilution provisions thereof, the Conversion Price then in effect shall forthwith be readjusted to such Conversion Price as would have been obtained had the
Conversion Price adjustment that was originally made upon the issuance of such Option, Right to Acquire Common Stock or Convertible Security which were not exercised, converted or exchanged prior to such change been made upon the basis of such
change, but no further adjustment shall be made for the actual issuance of Common Stock upon the exercise or conversion of any such Option, Right to Acquire Common Stock or Convertible Security.
(iv) Waiver of Adjustment to Conversion Price. Notwithstanding the foregoing, the Requisite Holders can waive any adjustment to the
Conversion Price.
(v) Determination of Consideration. For purposes of this Section 6, the value of the consideration
received by the Corporation for the issuance of any Additional Shares of Common Stock shall be computed as follows:
|
(A) |
Cash and Property. Such consideration shall: |
-11-
|
(1) |
insofar as it consists of cash, be computed at the aggregate of cash received and the net present value of cash receivable (utilizing a discount rate of a rate per annum equal to LIBOR on the date of the issuance of
such Additional Shares plus 250 basis points) by the Corporation, excluding amounts paid or payable for accrued interest or accrued dividends; |
|
(2) |
insofar as it consists of property other than cash (subject to clause (3) below), be computed at the Fair Market Value thereof at the time of such issue; |
|
(3) |
insofar as it consists of securities, be computed as follows: (x) if traded on a securities exchange or quotation system, based on the average of the closing prices of the securities on such exchange or quotation
system over the 30 trading day period ending on the trading day immediately preceding the day the computation is being made, (y) if traded over-the-counter, based on the average of the closing bid or sale prices (whichever is applicable) over
the 45 trading day period ending on the trading day immediately preceding the day the computation is being made, and (z) the securities are not traded as set forth in (x) or (y) above, the Fair Market Value thereof at the time of such
issue; and |
|
(4) |
in the event Additional Shares of Common Stock are issued together with other shares or securities or other assets of the Corporation for consideration which covers both, be the proportion of such consideration so
received, computed as provided in clauses (1) through (3) above, as determined in good faith by the Board of Directors. |
|
(B) |
Options, Rights and Convertible Securities. The consideration per share received by the Corporation for Additional Shares of Common Stock deemed to have been issued pursuant to this Section 6,
relating to Options, Rights to Acquire Common Stock and Convertible Securities, shall be determined by dividing |
|
(1) |
the total amount, if any, received or receivable by the Corporation as consideration for the issuance of such Options, Rights or Convertible Securities, plus the aggregate amount of additional consideration expected to
be payable to the Corporation (as determined in good faith by the Board of Directors) upon the exercise of such Options or Rights to Acquire Common Stock or upon the conversion or exchange of such Convertible Securities, by |
-12-
|
(2) |
the maximum number of shares of Common Stock issuable upon the exercise of such Options or Rights to Acquire Common Stock or upon the conversion or exchange of such Convertible Securities. |
(vi) Upon Stock Dividends, Subdivisions or Splits. If, at any time after the date hereof, the number of shares of Common Stock
outstanding is increased by a stock dividend payable in shares of Common Stock or by a subdivision or split-up of shares of Common Stock, then, following the record date for the determination of holders of
Common Stock entitled to receive such stock dividend, or to be affected by such subdivision or split-up, the Conversion Price shall be appropriately decreased so that the number of shares of Common Stock
issuable on conversion of Series A Preferred Stock shall be increased in proportion to such increase in outstanding shares.
(vii) Upon
Combinations. If, at any time after the date hereof, the number of shares of Common Stock outstanding is decreased by a combination of the outstanding shares of Common Stock into a smaller number of shares of Common Stock, then, following the
record date to determine shares affected by such combination, the Conversion Price shall be appropriately increased so that the number of shares of Common Stock issuable on conversion of each share of Series A Preferred Stock shall be decreased in
proportion to such decrease in outstanding shares.
(viii) Capital Reorganization, Reclassification, Merger or Sale of Assets. If
at any time or from time to time there shall be (A) a capital reorganization of the Common Stock, (B) a reclassification of the Common Stock (other than a subdivision, combination, or exchange of shares provided for elsewhere in this
Section 6) or (C) a merger or consolidation of the Corporation with or into another corporation, or the sale of all or substantially all of the Corporations properties and assets to any other person, then, as a part of such
reorganization, reclassification, merger, or consolidation or sale, provision shall be made so that holders of Series A Preferred Stock, as the case may be, shall thereafter be entitled to receive upon conversion of the Series A Preferred Stock, the
kind and amount of shares of stock or other securities or property of the Corporation, or of the successor corporation resulting from such merger, consolidation or sale, to which such holder would have been entitled if such holder had converted its
shares of Series A Preferred Stock immediately prior to such capital reorganization, reclassification, merger, consolidation or sale. In any such case, appropriate adjustment shall be made in the application of the provisions of this
Section 6(d) with respect to the rights of the holders of the Series A Preferred Stock after the reorganization, reclassification, merger, consolidation or sale to the end that the provisions of this Section 6(d), including
adjustment of the Conversion Price then in effect for the Series A Preferred Stock and the number of shares issuable upon conversion of the Series A Preferred Stock) shall be applicable after that event in as nearly equivalent a manner as may be
practicable.
(e) Exercise of Conversion Privilege. In order to exercise the conversion privilege, the holder of any share of
Series A Preferred Stock shall surrender the certificate evidencing such share of Series A Preferred Stock, duly endorsed or assigned to the Corporation in blank, at any office or agency of the Corporation maintained for such purpose, accompanied by
written notice to the Corporation at such office or agency that the holder elects to convert such Series A Preferred Stock or, if less than the entire amount thereof is to be converted, the portion thereof to be converted. Series A Preferred Stock
shall be deemed to have been converted immediately
-13-
prior to the close of business on the date (the Conversion Date) of (i) the event triggering automatic conversion pursuant to Section 6(b) or
(ii) surrender of such shares of Series A Preferred Stock for conversion in accordance with the foregoing provisions, and at such time the rights of the holder of such shares of Series A Preferred Stock as a holder shall cease, and the person
or persons entitled to receive the Common Stock issuable upon conversion shall be treated for all purposes as the record holder or holders of such Common Stock as and after such time. As promptly as practicable on or after the Conversion Date, the
Corporation shall issue and shall deliver at any office or agency of the Corporation maintained for the surrender of Series A Preferred Stock a certificate or certificates for the number of full shares of Common Stock issuable upon conversion,
together with payment in lieu of any fraction of a share, as provided in Section 6(c). In the case of any certificate evidencing shares of Series A Preferred Stock that is converted in part only, upon such conversion the Corporation
shall also execute and deliver a new certificate evidencing the number of shares of Series A Preferred Stock that are not converted.
(f)
Notice of Adjustment of Conversion Price. Whenever the provisions of Section 6(d) require that the Conversion Price be adjusted as herein provided, the Corporation shall compute the adjusted Conversion Price in accordance with
Section 6(d) and shall prepare a certificate signed by the Corporations chief executive officer or chief financial officer setting forth the adjusted Conversion Price and showing in reasonable detail the facts upon which such
adjustment is based, and such certificate shall forthwith be filed at each office or agency maintained for such purpose for conversion of shares of Series A Preferred Stock and mailed by the Corporation at its expense to all holders of Series A
Preferred Stock at their last addresses as they shall appear in the stock register.
(g) Corporation to Reserve Common Stock. The
Corporation shall at all times reserve and keep available, free from preemptive rights, out of the authorized but unissued Common Stock or out of the Common Stock held in treasury, for the purpose of effecting the conversion of Series A Preferred
Stock, the full number of shares of Common Stock issuable upon the conversion of all outstanding shares of Series A Preferred Stock at any point during the next six (6) months. Before taking any action that would cause an adjustment reducing
the Conversion Price below the then par value (if any) of the shares of Common Stock deliverable upon conversion of the Series A Preferred Stock, the Corporation will take any corporate action that, in the opinion of its counsel, is necessary in
order that the Corporation may validly and legally issue fully paid and non-assessable shares of Common Stock at such adjusted Conversion Price.
(h) Taxes on Conversions. The Corporation will pay any and all original issuance, transfer, stamp and other similar taxes that may be
payable in respect of the issue or delivery of shares of Common Stock on conversion of Series A Preferred Stock pursuant hereto. The Corporation shall not, however, be required to pay any tax which may be payable in respect of any transfer involved
in the issue and delivery of shares of Common Stock in a name other than that of the holder of the share(s) of Series A Preferred Stock to be converted (nor shall the Corporation be responsible for any other taxes payable by the holders of the
Series A Preferred Stock), and no such issue or delivery shall be made unless and until the person requesting such issue has paid to the Corporation the amount of any such tax, or has established to the satisfaction of the Corporation that such tax
has been paid.
-14-
SECTION 7 Redemption of Series A Preferred Stock.
(a) Redemption at the Election of Holders of Series A Preferred Stock. At any time on or after the first anniversary of the Initial
Issue Date, the Requisite Holders may elect, by delivering an irrevocable written notice to the Corporation, to have the Corporation redeem all or any portion of the Series A Preferred Stock held by such holder at a price per share (the
Redemption Price) equal to the Stated Value per share plus an amount equal to all accrued and unpaid Regular Dividends thereon to the date of such notice. The Corporation shall, unless otherwise prevented by law, redeem from such
holder on the Redemption Date the number of shares of Series A Preferred Stock identified in such notice of election.
(b) Redemption
Closing. The closing of the Corporations redemption of the Series A Preferred Stock pursuant to this Section 7 shall take place at 11:00 a.m. Eastern Standard Time on the date that is no later than five (5) business days
following the determination of the Redemption Price pursuant to Section 7(a) (the Redemption Date) at the Corporations principal executive office or other mutually agreed upon location where the closing will
occur. At the closing, the Corporation shall pay to each holder of Series A Preferred Stock from whom shares of Series A Preferred Stock are being redeemed an amount equal to the aggregate applicable Redemption Price for all such shares against
receipt from such holder of the certificate or certificates, duly endorsed or assigned to the Corporation in blank, representing the shares of Series A Preferred Stock being redeemed. All such payments shall be made by wire transfer of immediately
available funds or, if any such holder shall not have specified wire transfer instructions to the Corporation prior to the closing, by certified or official bank check payable to the order of the holder. In the case of any certificate evidencing
shares of Series A Preferred Stock that is redeemed in part only, upon such redemption the Corporation shall also execute and deliver a new certificate evidencing the number of shares of Series A Preferred Stock that are not redeemed.
(c) Insufficient Funds. If the Corporation shall not be permitted, or shall not have funds legally available in the amount necessary,
to redeem all shares of Series A Preferred Stock to be redeemed on the applicable Redemption Date, then the Series A Preferred Stock shall be redeemed by the Corporation on such Redemption Date to the maximum extent the Corporation is permitted and
has funds legally available on a pro rata basis, in accordance with the number of shares to be redeemed from each such holder of Series A Preferred Stock. The Corporation shall immediately redeem such shares of Series A Preferred Stock
upon the termination of such legal prohibition and at any time thereafter when additional funds of the Corporation are legally available for the redemption of such shares of Series A Preferred Stock, such funds will be used, at the end of the next
succeeding fiscal quarter, to redeem the balance of such shares, or such portion thereof for which funds are then legally available, on the basis set forth above.
(d) Effect of Redemption. From and after the close of business on the applicable Redemption Date, unless there shall have been a
default in the payment of the Redemption Price, all rights (except the right to receive the Redemption Price) of the holders of Series A Preferred Stock with respect to the shares of Series A Preferred Stock to be redeemed on such date shall cease
and terminate, and such shares shall not thereafter be transferred on the books of the Corporation or be deemed to be outstanding for any purpose whatsoever whether or not the certificates representing such shares have been received by the
Corporation; provided, however, that, notwithstanding anything contained herein to the contrary, (A) if the Corporation defaults in the payment of the Redemption Price, the rights of such holders with respect to such shares of
-15-
Series A Preferred Stock shall continue until the Corporation cures such default, and (B) without limiting any other rights of such holders, upon the occurrence of a subsequent Liquidation
or Deemed Liquidation, with respect to the shares of Series A Preferred Stock in respect of which the payment of the Redemption Price has not occurred, such holders shall be accorded the Liquidation rights set forth in Section 5 hereof
in respect of such remaining shares, as if no prior redemption request had been made. The shares of Series A Preferred Stock not redeemed shall remain outstanding and entitled to all rights and preferences provided herein.
(e) Miscellaneous. Neither the Corporation nor any Subsidiary shall offer to purchase, redeem or acquire any shares of Series A
Preferred Stock other than pursuant to the terms of this Certificate of Designations or pursuant to a purchase offer made to all holders of Series A Preferred Stock pro rata based upon the number of such shares owned by each such
holder.
SECTION 8 Right of First Offer. Unless otherwise waived by the Requisite Holders, on the terms and subject to the
conditions of this Section 8 and applicable securities laws, if the Corporation or any of its Subsidiaries proposes to offer or sell any New Securities, the Corporation shall first offer such New Securities to each holder of Series A
Preferred Stock (a Series A Stockholder). A Series A Stockholder shall be entitled to apportion the right of first offer hereby granted to it in such proportions as it deems appropriate, among (i) itself, (ii) its
Affiliates and (iii) its beneficial interest holders, such as limited partners, members or any other person having beneficial ownership, as such term is defined as such term is defined in Rule 13d-3 promulgated under the Securities
Exchange Act of 1934, as amended, of such Series A Stockholder.
(a) The Corporation shall give notice (the Offer
Notice) to each Series A Stockholder, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to
offer such New Securities.
(b) By notification to the Corporation within twenty (20) days after the Offer Notice is given, each
Series A Stockholder may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion of the shares of Series A Preferred Stock then held
by such Series A Stockholder relative to number of shares of Series A Preferred Stock outstanding. Alternatively, the Requisite Holders may propose alternative terms and pricing for the New Securities (the Counter Proposal). Any
unsubscribed portion of such New Securities shall be offered to the subscribing Series A Stockholders pro rata, based on their relative number of shares of Series A Preferred Stock. The closing of any sale pursuant to this
Section 8(b) shall occur within sixty (60) days of the date that the Offer Notice is given or such other time as may be agreed between the Company and the Requisite Holders.
(c) If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in Section 8(b),
the Corporation may, during the ninety (90) day period following the expiration of the period provided in Section 8(b), offer and sell the remaining unsubscribed portion of such New Securities to any person or persons at a price not
less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice or Counter Proposal, as applicable. If the Corporation does not enter into an agreement for the sale of the New Securities within such period, or if
such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Series A Stockholders in
accordance with this Section 8.
-16-
SECTION 9 Ranking.
For purposes of this Certificate of Designation, any stock of any class or classes of the Corporation shall be deemed to rank:
(a) prior to the shares of this Series A Preferred Stock, either as to dividends or upon liquidation, if the holders of such class or classes
shall be entitled to the receipt of dividends or of amounts distributable upon dissolution, liquidation or winding up of the Corporation, as the case may be, in preference or priority to the holders of shares of this Series A Preferred Stock (any
such securities, Senior Securities);
(b) pari passu to the shares of this Series A Preferred Stock, either as to
dividends or upon liquidation, if the holders of such class or classes shall be entitled to the receipt of dividends or of amounts distributable upon dissolution, liquidation or winding up of the Corporation, as the case may be, pari passu with the
holders of shares of this Series A Preferred Stock (any such securities, Parity Securities);
(c) junior to shares of
this Series A Preferred Stock, either as to dividends or upon liquidation, if such class shall be Common Stock or if the holders of shares of this Series A Preferred Stock shall be entitled to receipt of dividends or of amounts distributable upon
dissolution, liquidation or winding up of the Corporation, as the case may be, in preference or priority to the holders of shares of such class or classes (any such securities, Junior Securities).
SECTION 10 Amendment and Waiver. Notwithstanding anything to the contrary herein, the amendment or waiver of any provisions of
this Certificate of Designation can be approved by the Requisite Holders.
-17-
IN WITNESS WHEREOF, the Corporation has caused this Certificate of Designations,
Preferences and Rights to be duly executed by its President, this 11th day of March 2015.
|
|
|
|
|
By: |
|
/s/ Cary G. Vance |
|
|
Name: |
|
Cary G. Vance |
|
|
Title: |
|
President & CEO |
Exhibit 4.1
Execution Version
SECURITIES PURCHASE AGREEMENT
This Securities Purchase Agreement (this Agreement) is dated as of March 9, 2015, between Hansen Medical, Inc., a
Delaware corporation (the Company), and each purchaser identified on Exhibit A hereto (each, including its successors and assigns, a Purchaser and collectively, the Purchasers).
WHEREAS, on the terms and subject to the conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of
1933, as amended (the Securities Act), and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities
of the Company as more fully described in this Agreement.
NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this
Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:
ARTICLE I.
DEFINITIONS
1.1 Definitions. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the
following terms have the meanings set forth in this Section 1.1:
19.99% Restriction shall
have the meaning ascribed to such term in Section 5.1(d).
Affiliate means any Person that,
directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.
Agreement shall have the meaning ascribed to such term in the preamble.
Amended and Restated IRA means that certain Amended and Restated Investor Rights Agreement, dated as of
August 11, 2014, by and among the Company, the Purchasers and the other purchasers named therein.
Applicable
Laws shall have the meaning ascribed to such term in Section 3.22.
Auditor shall
have the meaning ascribed to such term in Section 3.11.
Authorizations shall have the
meaning ascribed to such term in Section 3.22.
Benefit Plans shall have the meaning
ascribed to such term in Section 3.3.
Board of Directors means the board of directors of
the Company.
Business Day means any day except any Saturday, any Sunday, any day which is a federal
holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.
Certificate of Designations shall have the meaning ascribed to
such term in Section 2.1(b).
Closing shall have the meaning ascribed to such term in
Section 2.2.
Closing Date shall have the meaning ascribed to such term in
Section 2.2.
Code shall have the meaning ascribed to such term in Section 3.17.
Commission means the United States Securities and Exchange Commission.
Common Stock means the common stock of the Company, par value $0.0001 per share, and any other class of
securities into which such securities may hereafter be reclassified or changed.
Company shall have the
meaning ascribed to such term in the preamble.
Company Stockholders Meeting shall have the
meaning ascribed to such term in Section 5.1(a).
Corporate Actions shall have the meaning
ascribed to such term in Section 5.1(d).
Disclosure Schedules shall have the meaning
ascribed to such term in ARTICLE III.
Effective Date means the earliest of the date that
(a) the Registration Statement has been declared effective by the Commission, (b) all of the Registrable Securities (as defined in the Second Amended and Restated IRA) have been sold pursuant to Rule 144 or may be sold pursuant to Rule 144
without the requirement for the Company to be in compliance with the current public information required under Rule 144 and without volume or manner-of-sale restrictions or (c) following the one year anniversary of the Closing Date provided
that no holder of Registrable Securities is an Affiliate of the Company, all of the Registrable Securities may be sold pursuant to an exemption from registration under Section 4(a)(1) of the Securities Act without volume or manner-of-sale
restrictions and Company counsel has delivered to such holders a standing written unqualified opinion that resales may then be made by such holders of the Registrable Securities pursuant to such exemption which opinion shall be in form and substance
reasonably acceptable to such holders.
Environmental Laws shall have the meaning ascribed to such term
in Section 3.16.
ERISA shall have the meaning ascribed to such term in
Section 3.17.
2
Except as disclosed in the SEC Reports shall be construed to
mean only those matters that are reasonably apparent and fairly disclosed in the SEC Reports (excluding any disclosures set forth in any risk factor section and in any section relating to forward-looking statements to the extent they are cautionary,
predictive or forward-looking). For purposes of this definition, SEC Reports shall only include SEC Reports filed with or furnished to the Commission since January 1, 2014.
Exchange Act means the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder.
Exchange Rules shall have the meaning ascribed to such term in
Section 3.10.
Existing Credit Agreement shall have the meaning ascribed to such term in
Section 3.3.
FCPA means the Foreign Corrupt Practices Act of 1977, as amended.
FDA means the U.S. Food and Drug Administration.
GAAP shall have the meaning ascribed to such term in Section 3.8.
Governmental Authority shall have the meaning ascribed to such term in Section 3.22.
Intellectual Property means (i) worldwide patents, patent applications, invention disclosures and other
rights of invention, filed with any governmental authority, and all reissues, divisions, renewals, extensions, provisionals, continuations and continuations-in-part thereof and all reexamined patents or other applications or patents claiming the
benefit of the filing date of any of the foregoing; (ii) worldwide (A) registered trademarks and service marks and registrations and applications for such registrations, and (B) unregistered trademarks and service marks, trade names,
fictitious business names, corporate names, trade dress, logos, product names and slogans, including any common law rights; in each case together with the goodwill associated therewith; (iii) worldwide (A) registered copyrights in
published or unpublished works, mask work rights and similar rights, including rights created under Sections 901-914 of Title 17 of the United States Code, mask work registrations, and copyright applications for registration, including any renewals
thereof, and (B) any unregistered copyrightable works and other rights of authorship in published or unpublished works; (iv) worldwide (A) internet domain names; (B) website content; (C) telephone numbers; and (D) moral
rights and publicity rights; (v) any computer program or other software (irrespective of the type of hardware for which it is intended), including firmware and other software embedded in hardware devices, whether in the form of source code,
assembly code, script, interpreted language, instruction sets or binary or object code (including compiled and executable programs), including any library, component or module of any of the foregoing, including, in the case of source code, any
related images, videos, icons, audio or other multimedia data or files, data files, and header, development or compilations tools, scripts, and files, and (vi) worldwide confidential or proprietary information or trade
3
secrets, including technical information, inventions and discoveries (whether or not patentable and whether or not reduced to practice) and improvements thereto, know-how, processes, discoveries,
developments, designs, techniques, plans, schematics, drawings, formulae, preparations, assays, surface coatings, diagnostic systems and methods, patterns, compilations, databases, database schemas, specifications, technical data, inventions,
concepts, ideas, devices, methods, and processes; and includes any rights to exclude others from using or appropriating any Intellectual Property Rights, including the rights to sue for or assets claims against and remedies against past, present or
future infringements or misappropriations of any or all of the foregoing and rights of priority and protection of interests therein, and any other proprietary, intellectual property or other rights relating to any or all of the foregoing anywhere in
the world.
Material Adverse Effect means a material adverse effect on (i) the assets, liabilities,
results of operations, condition (financial or otherwise), business, or prospects of the Company and its Subsidiaries taken as a whole, or (ii) the ability of the Company to perform its obligations under the Transaction Documents. For the
avoidance of doubt, a breach or conflict with the Existing Credit Agreement shall be deemed to be a Material Adverse Effect.
Nasdaq means The NASDAQ Stock Market, LLC.
Nasdaq Rules shall have the meaning ascribed to such term in Section 3.10.
Occupational Laws shall have the meaning ascribed to such term in Section 3.17.
Oracle shall have the meaning ascribed to such term within definition of Principal Purchasers.
Person means an individual or corporation, partnership, trust, incorporated or unincorporated
association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.
Preferred Shares shall have the meaning ascribed to such term in Section 2.1(a).
Price Per Share shall have the meaning ascribed to such term in Section 2.1(a).
Principal Purchasers means Oracle Partners, LP, Oracle Institutional Partners, LP and Oracle Ten Fund
Master, LP (together, Oracle) and the Schuler Family Foundation and their respective successors and assigns.
Proxy Statement shall have the meaning ascribed to such term in Section 5.1(c).
Purchase Price shall have the meaning ascribed to such term in Section 2.1(a).
Purchaser Party shall have the meaning ascribed to such term in Section 5.9.
Purchasers shall have the meaning ascribed to such term in the preamble.
4
Recommendation shall have the meaning ascribed to such term in
Section 5.1(a).
Registration Statement shall have the meaning ascribed to such term in the
Second Amended and Restated IRA.
Requisite Stockholder Approval means (i) the favorable vote of
the holders of at least 66 2/3rds of the outstanding Common Stock to approve the amendment to the Certificate of Incorporation pursuant to Section 5.1(d)(x) and (ii) the favorable vote of the holders of a majority of the outstanding
Common Stock participating at the Company Stockholders Meeting with respect to the other Corporate Actions.
Rights Offering shall have the meaning ascribed to such term in Section 5.2.
Rule 144 means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be
amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.
SEC Reports shall have the meaning ascribed to such term in Section 3.7.
Second Amended and Restated IRA means the Second and Restated Investor Rights Agreement, dated as of the
Closing Date, among the Company, the Purchasers and the other purchasers named therein, in the form of Exhibit C attached hereto.
Securities means the Preferred Shares, any shares of Common Stock issued or issuable upon the full
conversion of the Preferred Shares, the Warrants and the Warrant Shares.
Securities Act shall have the
meaning ascribed to such term in the recitals.
Series D Warrants means the Series D warrants
exercisable to purchase shares of Common Stock issued pursuant to that Exchange Agreement, dated as of July 30, 2014, by and among the Company and the warrantholders named therein.
Series E Warrants shall have the meaning ascribed to such term in Section 2.1(a).
Subsidiary means any subsidiary of the Company as set forth on Schedule 3.1 and shall, where
applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.
Trading Day means a day on which the principal Trading Market is open for trading.
Trading Market means any of the following markets or exchanges on which the Common Stock is listed or quoted
for trading on the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any successors to any of the foregoing).
5
Transaction Documents means this Agreement, the Warrants, the
Second Amended and Restated IRA, the Certificate of Designations, all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.
Transfer Agent means Computershare Trust Company, N.A., the current transfer agent of the Company, with a
mailing address of 330 N. Brand Blvd., Suite 701, Glendale, California 91203-2389 and a telephone number of (732) 512-3172, and any successor transfer agent of the Company.
Warrant Shares shall have the meaning ascribed to such term in Section 2.1(a).
Warrants shall have the meaning ascribed to such term in Section 2.1(a).
ARTICLE II.
PURCHASE
AND SALE
2.1 Purchase and Sale.
(a) Upon the terms and subject to the conditions set forth in this Agreement, the Company agrees to issue and sell to the Purchasers, and the
Purchasers agree, severally and not jointly, to purchase from the Company an aggregate of 53,846 shares of Series A Convertible Preferred Stock, par value $0.0001 per share, of the Company (collectively, the Preferred Shares) in
the amounts set forth opposite their respective names on Exhibit A, at a price per Preferred Share equal to $650.00 (the Price Per Share and the purchase price for the Preferred Shares, the Purchase
Price). Contemporaneously, in conjunction with the foregoing purchase and sale, the Company agrees to issue, and the Purchasers shall receive, Series E warrants in the form attached hereto on Exhibit D (the
Warrants or Series E Warrants), exercisable to purchase an aggregate of 53,846,000 shares of Common Stock (the Warrant Shares) in the amounts set forth opposite their respective names on
Exhibit A.
(b) At or prior to the Closing, the Company shall file the Certificate of Designations of the Series A Convertible
Preferred Stock, in the form attached hereto on Exhibit B, with the Secretary of State of the State of Delaware as an amendment to the Companys Certificate of Incorporation (the Certificate of Designations).
2.2 Closing. The closing of the purchase and sale of the Preferred Shares and Warrants (the Closing) shall take
place at the offices of Sidley Austin LLP located at 555 California Street, 20th Floor, San Francisco, California 94104, on March 11, 2015, following the satisfaction or waiver
of the conditions set forth in Section 2.4, or at such other time and place or on such date as the Principal Purchasers and the Company may agree upon (such date is hereinafter referred to as the Closing Date). At the
Closing, the applicable Purchase Price shall be paid by the applicable Purchasers in cash, by wire transfer of immediately available funds, to an account previously designated in writing by the Company against the issuance by the Company of the
Preferred Shares and Warrants.
6
2.3 Deliveries.
(a) Except as specified in clauses (ii) and (iii) below, on or prior to the Closing Date, the Company shall deliver
or cause to be delivered to each Purchaser the following:
(i) the Second Amended and Restated IRA duly executed by the
Company;
(ii) a certificate evidencing the number of Preferred Shares set forth opposite such Purchasers name on
Exhibit A hereto, registered in the name of such Purchaser (such certificates to be delivered as promptly as practicable after the Closing Date but in no event more than three Trading Days after the Closing Date);
(iii) Warrants registered in the name of such Purchaser to purchase up to a number of shares of Common Stock set forth opposite
such Purchasers name on Exhibit A hereto (such Warrant certificates to be delivered as promptly as practicable after the Closing Date but in no event more than three Trading Days after the Closing Date);
(iv) a Certificate, executed on behalf of the Company by its Chief Executive Officer and its Chief Financial Officer, dated as
of the Closing Date, certifying to the fulfillment of the conditions specified in subsections (i), (ii), (iv), (v), (vi) and (vii) of Section 2.4(b); and
(v) a Certificate, executed on behalf of the Company by its Secretary, dated as of the Closing Date, (A) certifying the
resolutions adopted by the Board of Directors of the Company approving the Transaction Documents (in forms approved by authorized officers) and the transactions contemplated by this Agreement, including the issuance of the Preferred Shares, the
shares of Common Stock issuable upon the conversion of the Preferred Shares, the Warrants and the Warrant Shares and the Corporate Actions (subject to, as applicable, obtaining the Requisite Stockholder Approval), (B) certifying the current
versions of the Certificate of Incorporation, the Certificate of Designations, and the Bylaws of the Company and (C) certifying as to the signatures and authority of persons signing the Transaction Documents and related documents on behalf of
the Company.
(b) On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the
following:
(i) the Second Amended and Restated IRA duly executed by such Purchaser; and
(ii) the applicable Purchase Price by wire transfer to the account specified by the Company.
2.4 Closing Conditions.
7
(a) The obligations of the Company hereunder with respect to any Purchaser in
connection with the Closing are subject to the following conditions being met:
(i) the accuracy in all material respects
on the Closing Date of the representations and warranties of such Purchaser contained herein (unless as of a specific date therein in which case they shall be accurate as of such date);
(ii) all obligations, covenants and agreements of such Purchaser required to be performed at or prior to the Closing Date shall
have been performed in all material respects; and
(iii) the delivery by such Purchaser of the items set forth in
Section 2.3(b) of this Agreement.
(b) The respective obligations of the Purchasers hereunder in connection
with the Closing are subject to the following conditions being met:
(i) the representations and warranties made by the
Company in ARTICLE III hereof qualified as to materiality shall be true and correct as of the date hereof and the Closing Date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case
such representation or warranty shall be true and correct as of such earlier date, and, the representations and warranties made by the Company in ARTICLE III hereof not qualified as to materiality shall be true and correct in all material
respects as of the date hereof and the Closing Date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in all material respects as
of such earlier date;
(ii) all obligations, covenants and agreements of the Company required to be performed at or prior
to the Closing Date, whether under this Agreement or the other Transaction Documents, shall have been performed in all material respects;
(iii) the delivery by the Company of the items set forth in Section 2.3(a) of this Agreement;
(iv) except for the Requisite Stockholder Approval, the Company shall have obtained any and all consents, permits, approvals,
registrations and waivers necessary or appropriate for the consummation of the transactions and the full exercise of the Purchasers rights, including the issuance of the Preferred Shares, the full conversion of the Preferred Shares into shares
of Common Stock, the issuance of the Warrants and the full exercise of the Warrants, as contemplated by the Transaction Documents;
(v) no judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including any
bankruptcy court or judge, or any order of or by any governmental authority, shall have been issued, and no
8
action or proceeding shall have been instituted by any governmental authority, enjoining or preventing the consummation of the transactions contemplated hereby or in the other Transaction
Documents;
(vi) no stop order or suspension of trading shall have been imposed by Nasdaq, the Commission or any other
governmental or regulatory body with respect to public trading in the Common Stock; and
(vii) there shall have been no
Material Adverse Effect with respect to the Company since the date hereof.
ARTICLE III.
REPRESENTATIONS AND WARRANTIES OF THE COMPANY
The Company hereby represents and warrants to the Purchasers that, except as set forth in the schedules delivered herewith (collectively, the
Disclosure Schedules):
3.1 Organization, Good Standing and Qualification. The Company is duly organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation and has all requisite corporate power and authority to carry on its business as now conducted and to own its properties. Each of the Subsidiaries is duly
organized, validly existing and in good standing under the laws of the jurisdiction of its formation and has all requisite corporate power and authority to carry on its business as now conducted and to own its properties unless the failure to be so
organized and to have such power and authority has not had and could not reasonably be expected to have a Material Adverse Effect. Each of the Company and its Subsidiaries is duly qualified to do business as a foreign corporation and is in good
standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property makes such qualification or leasing necessary unless the failure to so qualify has not had and could not reasonably be expected to have a
Material Adverse Effect. The Companys Subsidiaries are listed on Schedule 3.1 hereto.
3.2 Authorization; Enforcement.
Subject to the Requisite Stockholder Approval, the Company has all corporate right, power and authority to enter into the Transaction Documents and to consummate the transactions contemplated hereby and thereby. Subject to the Requisite Stockholder
Approval, all corporate action on the part of the Company, its directors and stockholders necessary for the authorization, execution, delivery and performance of the Transaction Documents by the Company, the authorization, sale, issuance and
delivery of the Securities contemplated herein and the performance of the Companys obligations hereunder and thereunder has been taken. The Transaction Documents have been (or upon delivery will have been) duly executed and delivered by the
Company and constitute the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with their terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of creditors rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable
remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.
9
3.3 Capitalization. Schedule 3.3 sets forth as of the date hereof (a) the
authorized capital stock of the Company; (b) the number of shares of capital stock issued and outstanding; (c) the number of shares of capital stock remaining available for issuance pursuant to the Companys stock plans; and
(d) the number of shares of capital stock issuable and reserved for issuance pursuant to outstanding securities exercisable for, or convertible into or exchangeable for, any shares of capital stock of the Company. All of the issued and
outstanding shares of the Companys capital stock have been duly authorized and validly issued and are fully paid, nonassessable and free of pre-emptive rights and were issued in full compliance with applicable state and federal securities law
and any rights of third parties. All of the issued and outstanding shares of capital stock of each Subsidiary have been duly authorized and validly issued and are fully paid, nonassessable and free of pre-emptive rights, were issued in full
compliance with applicable state and federal securities law and any rights of third parties and are owned by the Company, beneficially and of record, subject to no lien, encumbrance or other adverse claim, except the issued and outstanding capital
stock, membership units or other securities owned or held of record by the Company in its Subsidiaries that have been pledged as collateral under that certain Amended and Restated Loan and Security Agreement, dated as of August 23, 2013, by and
among the Company, the entities from time to time party thereto as Lenders and White Oak Global Advisors, LLC (the Existing Credit Agreement). No Person is entitled to pre-emptive or similar statutory or contractual rights with
respect to any securities of the Company. Except as described on Schedule 3.3, there are no outstanding warrants, options, convertible securities or other rights, agreements or arrangements of any character under which the Company or any of
its Subsidiaries is or may be obligated to issue any equity securities of any kind and except as contemplated by this Agreement and shares issued to officers, directors, employees, and consultants pursuant to employee benefit plans (Benefit
Plans) as disclosed in the SEC Reports; and neither the Company nor any of its Subsidiaries has any commitments for the issuance of any equity securities of any kind, other than in connection with this Agreement or as described on
Schedule 3.3. Except as described on Schedule 3.3 and except for the Amended and Restated IRA and Benefit Plans, there are no voting agreements, buy-sell agreements, option or right of first purchase agreements or other agreements of
any kind among the Company and any of the securityholders of the Company relating to the securities of the Company held by them. Except as described on Schedule 3.3 and except as provided in the Amended and Restated IRA, no Person has the
right to require the Company to register any securities of the Company under the Securities Act, whether on a demand basis or in connection with the registration of securities of the Company for its own account or for the account of any other
Person. The issuance and sale of the Preferred Shares and Warrants and the issuance of Common Stock upon the conversion of the Preferred Shares and the exercise of the Warrants hereunder, subject to the Requisite Stockholder Approval, will not
obligate the Company to issue shares of Common Stock or other securities to any other Person (other than the Purchasers) and will not result in the adjustment of the exercise, conversion, exchange or reset price of any outstanding security. Except
as described on Schedule 3.3, the Company does not have outstanding stockholder purchase rights or poison pill or any similar arrangement in effect giving any Person the right to purchase any equity interest in the Company upon
the occurrence of certain events.
3.4 Issuance; Reservation of Shares. The issuance of the Preferred Shares has been duly and
validly authorized by all necessary corporate and stockholder action, and the Preferred Shares, when issued and paid for pursuant to this Agreement and, subject to the Requisite Stockholder Approval, the shares of Common Stock issuable upon the
conversion of such
10
Preferred Shares, will be validly issued, fully paid and non-assessable, and shall be free and clear of all encumbrances and restrictions (other than as provided in the Transaction Documents).
The issuance of the Warrants has been duly and validly authorized by all necessary corporate and stockholder action, and the Warrant Shares, subject to the Requisite Stockholder Approval, when issued upon the due exercise of the Warrants, will be
validly issued, fully paid and non-assessable, and shall be free and clear of all encumbrances (other than as provided in the Transaction Documents). Subject to and after the receipt of the Requisite Stockholder Approval, the Company will have
reserved, and will continue to reserve at all times that the Preferred Shares or Warrants remain outstanding, such number of shares of Common Stock sufficient to enable the conversion of all Preferred Shares and the full exercise of the Warrants and
Series D Warrants then outstanding.
3.5 No Conflicts. Except as set forth in Schedule 3.5, subject to the Requisite
Stockholder Approval, the execution, delivery and performance of the Transaction Documents by the Company and the issuance and sale of the Securities will not conflict with or result in a breach or violation of any of the terms and provisions of, or
constitute a default under (i) the Companys Certificate of Incorporation and Bylaws (true and complete copies of which have been made available to the Purchasers through the EDGAR system), or (ii)(a) any statute, rule, regulation or order
of any Governmental Authority, any Subsidiary or any of their respective assets or properties, (b) the Existing Credit Agreement or (c) except for any such conflict, breach, violation or default that would not reasonably be expected to
have a Material Adverse Effect, any other agreement or instrument to which the Company or any Subsidiary is a party or by which the Company or a Subsidiary is bound or to which any of their respective assets or properties is subject.
3.6 Filings, Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any
notice to, or make any filing or registration with, any Governmental Authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents (including, for the avoidance of doubt, any
consents or approvals related to the Existing Credit Agreement), other than filings that have been made, or will be made, or consents that have been obtained, or will be obtained, pursuant to the rules and regulations of Nasdaq, applicable state
securities laws and post-sale filings pursuant to applicable state and federal securities laws which the Company undertakes to file or obtain within the applicable time periods.
3.7 SEC Reports. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the
Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, since January 1, 2014 (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein,
being collectively referred to herein as the SEC Reports) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their
respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or
omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Company has not received any letters of comment
from the staff of the Commission that have not been resolved as of the date hereof.
11
3.8 Financial Statements. The financial statements of the Company included in the SEC
Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with
United States generally accepted accounting principles applied on a consistent basis during the periods involved (GAAP), except as may be otherwise specified in such financial statements or the notes thereto and except that
unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of
operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.
3.9 Material Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements
included within the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof: (i) there has been no event, occurrence or development that has had or that could reasonably be expected to have a
Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and
(B) liabilities not required to be reflected in the Companys financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting or changed its principal
registered public accounting firm, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its
capital stock and (v) the Company has not issued any equity securities, except pursuant to existing Company equity compensation plans. The Company does not have pending before the Commission any request for confidential treatment of
information.
3.10 Internal Controls. The Company maintains a system of internal accounting controls sufficient to provide
reasonable assurances that (A) transactions are executed in accordance with managements general or specific authorization; (B) transactions are recorded as necessary to permit preparation of financial statements in conformity with
GAAP and to maintain accountability for assets; (C) access to assets is permitted only in accordance with managements general or specific authorization; and (D) the recorded accountability for assets is compared with existing assets
at reasonable intervals and appropriate action is taken with respect to any differences. Except as disclosed in the SEC Reports, the Companys internal control over financial reporting is effective and none of the Company, the Board of
Directors and audit committee is aware of any significant deficiencies or material weaknesses (each as defined by the Public Company Accounting Oversight Board) in its internal control over financial reporting, or any fraud,
whether or not material, that involves management or other employees of the Company who have a significant role in the Companys internal controls; and since the end of the latest audited fiscal year, there has been no change in the
Companys internal control over financial reporting (whether or not remediated) that has materially affected, or is reasonably likely to materially affect, the Companys internal control over financial reporting. The Board of
12
Directors has, subject to the exceptions, cure periods and the phase in periods specified in the applicable stock exchange rules (Exchange Rules), validly appointed an audit
committee to oversee internal accounting controls whose composition satisfies the applicable requirements of the Exchange Rules and the Board of Directors and/or the audit committee has adopted a charter that satisfies the requirements of the
Exchange Rules. The Board of Directors has validly appointed an audit committee whose composition satisfies the applicable requirements of Rule 5605(c)(2) of the Nasdaq Listing Standards (the Nasdaq Rules) and the Board of
Directors and/or the audit committee has adopted a charter that satisfies the requirements of Rule 5605(c)(1) of the Nasdaq Rules. Neither the Board of Directors nor the audit committee has been informed, nor is any director of the Company aware, of
(A) any significant deficiencies in the design or operation of the Companys internal controls which could adversely affect the Companys ability to record, process, summarize and report financial data or any material weakness in the
Companys internal controls; or (B) any fraud, whether or not material, that involves management or other employees of the Company who have a significant role in the Companys internal controls. No relationship, direct or indirect,
exists between or among the Company, on the one hand, and the directors, officers, stockholders, customers or suppliers of the Company, on the other hand, except as described in the SEC Reports which is required to be described in the SEC Reports.
The Company has not, directly or indirectly, extended or maintained credit, or arranged for the extension of credit, or renewed an extension of credit, in the form of a personal loan to or for any of its directors or executive officers in violation
of applicable laws, including Section 402 of the Sarbanes-Oxley Act of 2002. The Company has established and maintains disclosure controls and procedures (as defined in Rules 13a-15 and 15d-15 under the Exchange Act) and such controls and
procedures are effective in ensuring that material information relating to the Company is made known to the principal executive officer and the principal financial officer. The Company has utilized such controls and procedures in preparing and
evaluating the disclosures in the SEC Reports.
3.11 Accountant. To the Companys knowledge, Deloitte & Touche LLP
(the Auditor), which has expressed its opinion with respect to the Companys financial statements as of December 31, 2013 and 2012, respectively, and included in the SEC Reports (including the related notes), is
independent with respect to the Company within the meaning of Regulation S-X promulgated by the Commission and has been independent within such meaning at all times since its engagement by the Company. The Company has made
such disclosure of non-audit services performed by the Auditors in its proxy statements with respect to its annual meetings of its stockholders as is required under the Exchange Act, Securities Act and the rules and regulations of the Commission
promulgated thereunder, and all such non-audit services have been approved in advance by the audit committee of the Board of Directors. To the knowledge of the Company, the Auditor is a registered public accounting firm as required by the Securities
Act and the Sarbanes-Oxley Act of 2002 and the corresponding rules and regulations of the Commission promulgated thereunder.
3.12
Litigation. Except as set forth in the SEC Reports, there is not pending or, to the knowledge of the Company, threatened or contemplated, any action, suit or proceeding to which the Company or any of its Subsidiaries is a party or of which
any property or assets of the Company or any of its Subsidiaries is the subject before or by any Governmental Authority which, individually or in the aggregate, could reasonably be expected to result in any Material Adverse Effect. There are no
current or pending legal, governmental or regulatory actions, suits or proceedings that are required to be described in the SEC Reports that have not been so described.
13
3.13 Product Rights. Except as set forth in the SEC Reports, neither the Company nor any
Subsidiary has granted rights to develop, manufacture, produce, assemble, distribute, license, market or sell their products to any other person and is not bound by any agreement that affects either the Companys or any of its
Subsidiaries exclusive right to develop, manufacture, produce, assemble, distribute, license, market or sell their products.
3.14
Tax Matters. The Company and its Subsidiaries have timely filed all federal, state, local and foreign income and franchise tax returns required to be filed and are not in default in the payment of any material taxes which were payable
pursuant to said returns or any assessments with respect thereto, other than any which the Company or any of its Subsidiaries are contesting in good faith. There is no pending dispute with any taxing authority relating to any of such returns and the
Company has no knowledge of any proposed liability for any tax to be imposed upon the properties or assets of the Company or any of its Subsidiaries for which there is not an adequate reserve reflected in the Companys financial statements
included in the SEC Reports.
3.15 Insurance. The Company and each Subsidiary maintains in full force and effect insurance coverage
that is customary for comparably situated companies for the business being conducted and properties owned or leased by the Company and each Subsidiary, and the Company reasonably believes such insurance coverage to be adequate against all
liabilities, claims and risks against which it is customary for comparably situated companies to insure.
3.16 Environmental
Matters. The Company and its Subsidiaries (A) are in compliance with any and all applicable federal, state, local and foreign laws, rules, regulations, decisions and orders relating to the protection of human health and safety, the
environment or hazardous or toxic substances or wastes, pollutants or contaminants (collectively, Environmental Laws); (B) have received and are in material compliance with all permits, licenses or other approvals required of
them under applicable Environmental Laws to conduct their business; and (C) have not received notice of any actual or potential liability for the investigation or remediation of any disposal or release of hazardous or toxic substances or
wastes, pollutants or contaminants, except in any such case for any such failure to comply, or failure to receive required permits, licenses or approvals, or liability as would not, individually or in the aggregate, have a Material Adverse Effect.
3.17 Labor Relations. The Company and its Subsidiaries (A) are in compliance, in all material respects, with any and all
applicable foreign, federal, state and local laws, rules, regulations, treaties, statutes and codes promulgated by any and all Governmental Authorities (including pursuant to the Occupational Health and Safety Act) relating to the protection of
human health and safety in the workplace (Occupational Laws); (B) have received all material permits, licenses or other approvals required of it under applicable Occupational Laws to conduct their business as currently
conducted; and (C) are in compliance, in all material respects, with all terms and conditions of such permits, licenses or approvals. No action, proceeding, revocation proceeding, writ, injunction or claim is pending or, to the Companys
knowledge, threatened against the Company or any of its Subsidiaries relating to Occupational Laws, and the Company
14
does not have knowledge of any facts, circumstances or developments relating to its operations or cost accounting practices that could reasonably be expected to form the basis for or give rise to
such actions, suits, investigations or proceedings. Each employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (ERISA), that is maintained, administered
or contributed to by the Company, any of its Subsidiaries, or any of their affiliates for employees or former employees of the Company and its Subsidiaries has been maintained in material compliance with its terms and the requirements of any
applicable statutes, orders, rules and regulations, including but not limited to, ERISA and the Internal Revenue Code of 1986, as amended (the Code). No prohibited transaction, within the meaning of Section 406 of ERISA or
Section 4975 of the Code, has occurred with respect to any such plan excluding transactions effected pursuant to a statutory or administrative exemption; and for each such plan that is subject to the funding rules of Section 412 of the
Code or Section 302 of ERISA, no accumulated funding deficiency as defined in Section 412 of the Code has been incurred, whether or not waived, and the fair market value of the assets of each such plan (excluding for these
purposes accrued but unpaid contributions) exceeds the present value of all benefits accrued under such plan determined using reasonable actuarial assumptions.
3.18 Compliance. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has
occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it
is in violation of, any indenture, loan or credit agreement to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree, or
order of any Governmental Authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any Governmental Authority, including without limitation all foreign, federal, state and local laws relating to taxes,
environmental protection, occupational health and safety, product quality and safety and employment and labor matters, in each case in any material respect.
3.19 Certificates, Authorities and Permits. The Company and each of its Subsidiaries holds, and is operating in compliance in all
material respects with, all franchises, grants, authorizations, licenses, permits, easements, consents, certificates and orders of any Governmental Authority or self-regulatory body required for the conduct of its business and all such franchises,
grants, authorizations, licenses, permits, easements, consents, certifications and orders are valid and in full force and effect; and neither the Company nor any of its Subsidiaries has received notice of any revocation or modification of any such
franchise, grant, authorization, license, permit, easement, consent, certification or order or has reason to believe that any such franchise, grant, authorization, license, permit, easement, consent, certification or order will not be renewed in the
ordinary course; and the Company and each of its Subsidiaries is in compliance in all material respects with all applicable federal, state, local and foreign laws, regulations, orders and decrees.
3.20 Title to Assets. The Company and its Subsidiaries have good and marketable title to all property (whether real or personal)
described in the SEC Reports as being owned by them, in each case free and clear of all liens, claims, security interests, other encumbrances or defects except as described in the SEC Reports, and except those that could not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect. The property held under
15
lease by the Company and its Subsidiaries is held by them under valid, subsisting and enforceable leases with only such exceptions with respect to any particular lease as do not interfere in any
material respect with the conduct of the business of the Company or its Subsidiaries.
3.21 Intellectual Property. The Company and
its Subsidiaries own, possess, or can acquire on reasonable terms, all Intellectual Property necessary for the conduct of the their business as now conducted or as described in the SEC Reports to be conducted, except as such failure to own, possess,
or acquire such rights would not have a Material Adverse Effect. Except as set forth in the SEC Reports, (A) to the knowledge of the Company, there is no infringement, misappropriation or violation by third parties of any such Intellectual
Property, except as such infringement, misappropriation or violation would not have a Material Adverse Effect; (B) there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others challenging the
Companys or its Subsidiaries rights in or to any such Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such claim; (C) the Intellectual Property owned by the Company and its
Subsidiaries and, to the knowledge of the Company, the Intellectual Property licensed to the Company and its Subsidiaries have not been adjudged invalid or unenforceable, in whole or in part, and there is no pending or threatened action, suit,
proceeding or claim by others challenging the validity or scope of any such Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such claim; (D) there is no pending or threatened action,
suit, proceeding or claim by others that the Company or any of its Subsidiaries infringe, misappropriate or otherwise violate any Intellectual Property or other proprietary rights of others, neither the Company nor any of its Subsidiaries has
received any written notice of such claim and the Company is unaware of any other fact which would form a reasonable basis for any such claim; and (E) to the Companys knowledge, no employee of the Company or any of its Subsidiaries is in
or has ever been in violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with
a former employer where the basis of such violation relates to such employees employment with the Company or any of its Subsidiaries or actions undertaken by the employee while employed with the Company or any of its Subsidiaries.
3.22 FDA and Related Matters. Except as described in the SEC Reports, the Company and its Subsidiaries: (A) are and at all times
have been in full compliance with all statutes, rules, regulations, or guidances applicable to Company and its Subsidiaries and the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling,
promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the Company (Applicable Laws), except as could not, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect; (B) have not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the U.S. Food and Drug Administration or any other federal, state, local
or foreign governmental authority, court or arbitrator having authority over the Company (Governmental Authority) alleging or asserting noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances,
authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (Authorizations); (C) possess all material Authorizations and such Authorizations are valid and in full force and effect and
are not in
16
violation of any term of any such Authorizations; (D) have not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from
any Governmental Authority or third party alleging that any product operation or activity is in violation of any Applicable Laws or Authorizations and have no knowledge that any such Governmental Authority or third party is considering any such
claim, litigation, arbitration, action, suit, investigation or proceeding; (E) have not received notice that any Governmental Authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and
the Company has no knowledge that any such Governmental Authority is considering such action; and (F) have filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and
supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and correct in all material
respects on the date filed (or were corrected or supplemented by a subsequent submission). The studies, tests and preclinical and clinical trials conducted by or on behalf of the Company and its Subsidiaries were and, if still pending, are, in all
material respects, being conducted in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Applicable Laws and Authorizations, including, without limitation, the Federal Food,
Drug and Cosmetic Act and implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58 and 812; the descriptions of the results of such studies, tests and trials contained in the SEC Reports are accurate and complete in all material respects and
fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the SEC Reports, the Company is not aware of any studies, tests or trials the results of which the Company believes reasonably call into question
the study, test, or trial results described or referred to in the SEC Reports when viewed in the context in which such results are described and the clinical state of development; and neither the Company nor any of its Subsidiaries have received any
notices or correspondence from any Governmental Authority requiring the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company or any of its Subsidiaries.
3.23 Compliance with Nasdaq Continued Listing Requirements. Except as set forth in Schedule 3.23, the Company is, and has
no reason to believe that it will not, upon the issuance of the Securities hereunder, continue to be, in compliance with the listing and maintenance requirements for continued listing on Nasdaq. Assuming the representations and warranties of the
Purchasers set forth in ARTICLE IV are true and correct, subject to the Requisite Stockholder Approval, the consummation of the transactions contemplated by the Transaction Documents does not contravene the rules and regulations of Nasdaq.
There are no proceedings pending or, to the Companys knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any notice of, nor to the Companys knowledge
is there any basis for, the delisting of the Common Stock from Nasdaq.
3.24 Application of Takeover Protections. The Company and
the Board of Directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Companys Certificate of Incorporation or applicable laws that would prevent the Purchasers or the Company from
17
fulfilling their obligations or exercising their rights in full as contemplated under the Transaction Documents, including, without limitation, (i) the Companys issuance, and the
Purchasers receipt, of the Securities, (ii) the Purchasers right to fully convert the Preferred Shares into shares of Common Stock, (iii) the Purchasers right to fully exercise the Warrants and Series D Warrants for
shares of Common Stock and (iv) all other Corporate Actions.
3.25 Certain Fees. No brokerage or finders fees or
commissions are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction
Documents. The Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section 3.25 that may be due in connection with the
transactions contemplated by the Transaction Documents.
3.26 No Directed Selling Efforts or General Solicitation. Neither the
Company nor any Person acting on its behalf has conducted any general solicitation or general advertising (as those terms are used in Regulation D of the Commission) in connection with the offer or sale of any of the Securities.
3.27 No Integrated Offering. Neither the Company nor any of its Affiliates, nor any Person acting on its or their behalf has, directly
or indirectly, made any offers or sales of any Company security or solicited any offers to buy any security, under circumstances that would adversely affect reliance by the Company on Section 4(a)(2) of the Securities Act for the exemption from
registration for the transactions contemplated hereby or would require registration of the Securities under the Securities Act.
3.28
Private Placement. Assuming the accuracy of the Purchasers representations and warranties set forth in ARTICLE IV, no registration under the Securities Act is required for the offer and sale of the Securities by the Company to
the Purchasers as contemplated hereby.
3.29 Form S-3 Eligibility. The Company meets the eligibility requirements to register the
resale of the Securities for resale by the Purchaser on Form S-3 promulgated under the Securities Act.
3.30 Investment Company.
The Company is not and, after giving effect to the offering and sale of the Securities, will not be an investment company, as such term is defined in the Investment Company Act of 1940, as amended.
3.31 Foreign Corrupt Practices. Neither the Company, any of its Subsidiaries, nor, to the best knowledge of the Company, any director,
officer, agent, employee or other person associated with or acting on behalf of the Company or its Subsidiaries has (A) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political
activity; (B) made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; (C) violated or is in violation of any provision of the FCPA; or (D) made any unlawful bribe,
rebate, payoff, influence payment, kickback or other unlawful payment.
18
3.32 Regulation M Compliance. The Company has not, and to its knowledge no one acting on
its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Securities,
(ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the
Company.
3.33 Disclosure. No representation or warranty by the Company in this Agreement and no statement contained in the SEC
Reports or any certificate or other document furnished or to be furnished to the Purchasers pursuant to this Agreement contains any untrue statement of a material fact or omits to state a material fact necessary in order to make the statements
contained therein, in light of the circumstances under which they were made, not misleading.
ARTICLE IV.
REPRESENTATIONS AND WARRANTIES OF THE PURCHASERS
Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the date hereof and as of the Closing Date to the
Company as follows (unless as of a specific date therein):
4.1 Organization; Authority. Such Purchaser is either an individual or
an entity duly incorporated or formed, validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar power and authority to
enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such Purchaser of
the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to
which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance
with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors rights generally,
(ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.
4.2 Purchaser Status. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is an
accredited investor as defined in Rule 501 under the Securities Act. Such Purchaser is not a broker-dealer registered under Section 15 of the Exchange Act. Each Purchaser is acting alone in its determination as to whether to invest
in the Securities. Each such Purchaser is not party to any voting agreements or similar arrangements with respect to the Securities, except the Amended and Restated IRA. Each such Purchaser is not a member of a partnership, limited partnership,
syndicate, or other group for the purpose of acquiring, holding, voting or disposing of the Securities, provided, that (i) Jack W. Schuler and the Schuler Family Foundation may be viewed as a group and (ii) Oracle Partners, LP,
Oracle Ten Fund Master, LP, Oracle Institutional Partners, LP and Larry Feinberg may be viewed as a group.
19
4.3 General Solicitation. Such Purchaser is not purchasing the Securities as a result of
any advertisement, article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any other general solicitation or general
advertisement.
4.4 Purchase Entirely for Own Account. The Securities to be received by such Purchaser hereunder will be acquired
for such Purchasers own account, not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of the Securities Act, and such Purchaser has no present intention of selling, granting any
participation in, or otherwise distributing the same in violation of the Securities Act without prejudice, however, to such Purchasers right at all times to sell or otherwise dispose of all or any part of such Securities in compliance with
applicable federal and state securities laws. Nothing contained herein shall be deemed a representation or warranty by such Purchaser to hold the Securities for any period of time.
4.5 Experience of Such Purchaser. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the
economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.
4.6
Disclosure of Information. Such Purchaser has had an opportunity to receive all information related to the Company requested by it and to ask questions of and receive answers from the Company regarding the Company, its business and the terms
and conditions of the offering of the Securities. Such Purchaser acknowledges receipt of copies of the SEC Reports. Neither such inquiries nor any other due diligence investigation conducted by such Purchaser shall modify, limit or otherwise affect
such Purchasers right to rely on the Companys representations and warranties contained in this Agreement.
4.7 Restricted
Securities. Such Purchaser understands that the Securities are restricted securities and have not been registered under the Securities Act and may not be offered, resold, pledged or otherwise transferred except (i) pursuant to
an exemption from registration under the Securities Act or pursuant to an effective registration statement in compliance with Section 5 under the Securities Act and (ii) in accordance with all applicable securities laws of the states of
the United States and other jurisdictions.
4.8 Commissions. No Person will have, as a result of the transactions contemplated by
the Transaction Documents, any valid right, interest or claim against or upon the Company, any Subsidiary or a Purchaser for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on
behalf of such Purchaser.
The Company acknowledges and agrees that the representations contained in ARTICLE IV shall not modify, amend or affect
such Purchasers right to rely on the Companys representations and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document or any other document or instrument executed
and/or delivered in connection with this Agreement or the consummation of the transaction contemplated hereby.
20
ARTICLE V.
OTHER AGREEMENTS OF THE PARTIES
5.1 Requisite Stockholder Approval.
(a) Subject to applicable law, the rules and regulations of Nasdaq and the Companys Certificate of Incorporation and
Bylaws, the Company shall establish a record date for, call, give notice of, convene and hold a meeting of the stockholders of the Company (the Company Stockholders Meeting) as promptly as practicable following the date of
this Agreement (and in no event later than forty days after the commencement of the mailing of the Proxy Statement to the Companys stockholders), for the purpose of voting upon the approval, authorization and ratification of the Corporate
Actions set forth in Section 5.1(d), in accordance with applicable law and the rules and regulations of Nasdaq. Notwithstanding the foregoing, (i) if there are insufficient shares of the Companys Common Stock necessary to
conduct business at the Company Stockholders Meeting, the Company may extend the date of the Company Stockholders Meeting to the extent (and only to the extent) the Company reasonably determines that such delay is necessary in order to
conduct business at the Company Stockholders Meeting, (ii) the Company may delay the Company Stockholders Meeting to the extent (and only to the extent) the Company reasonably determines that such delay is required by applicable
law, and (iii) the Company may delay the Company Stockholders Meeting to the extent (and only to the extent) the Company reasonably determines that such delay is necessary to solicit sufficient proxies to secure the Requisite Stockholder
Approval. The Company shall solicit from stockholders of the Company proxies in favor of the approval, authorization and ratification of the Corporate Actions in accordance with applicable law and the rules and regulations of Nasdaq, and the
Companys Board of Directors shall (x) recommend that the Companys stockholders vote to adopt, authorize, approve and ratify the Corporate Actions (the Recommendation), (y) use its best efforts to solicit such
stockholders to vote in favor of the Corporate Actions and (z) take all other actions necessary or advisable to secure the favorable votes of such stockholders required to approve and effect all of the Corporate Actions. The Company shall
establish a record date for, call, give notice of, convene and hold the Company Stockholders Meeting in accordance with this Section 5.1(a), whether or not the Companys Board of Directors at any time subsequent to the date
hereof shall have changed its position with respect to its Recommendation or determined that any or all of the Corporate Actions are no longer advisable and/or recommended that stockholders of the Company reject it.
(b) Except as required to comply with fiduciary duties under applicable law, the Companys Board of Directors shall not
(i) withdraw or modify the Recommendation in a manner adverse to the Purchasers, or adopt or propose a resolution to withdraw or modify the Recommendation that is or becomes disclosed publicly and which can reasonably be interpreted to indicate
that the Companys Board of Directors or any committee thereof does not support the Corporate Actions or does not believe that the Corporate Actions are in the best interests of the Companys stockholders or (ii) fail to reaffirm,
without qualification, the Recommendation, or fail to state publicly, without qualification, that the Corporate Actions are in the best interests of the Companys stockholders after the Purchasers request in writing that such action be taken.
21
(c) As soon as practicable following the date of this Agreement, the Company
shall prepare and file with the Securities Exchange Commission the preliminary Proxy Statement (the Proxy Statement), which the Company shall use best efforts to complete and disseminate to the stockholders of the Company as soon
as practicable following such filing. No filing of, or amendment or supplement to, or correspondence with the Commission or its staff with respect to the Proxy Statement shall be made by the Company without providing the Purchasers and their counsel
a reasonable opportunity to review and comment thereon. The Company shall advise the Purchasers, promptly after it receives notice thereof, of any request by the Commission or its staff for an amendment or revisions to the Proxy Statement or
requests or comments thereon and responses thereto, and shall provide the Purchasers with copies of all correspondence between the Company and any of its advisors or representatives, on the one hand, and the Commission or its staff, on the other
hand.
(d) Corporate Actions means any and all corporate actions in furtherance of fully effectuating
(including, for the avoidance of doubt, the correction or removal of any limitations restricting the full exercise of the following actions, in whole or in part) (i) the Transaction Documents and the transactions contemplated hereby and
thereby, (ii) the full conversion of the Preferred Shares into Common Stock, (iii) the full exercise of all Series D Warrants and (iv) the full exercise of all Series E Warrants. Corporate Actions shall include, without limitation,
(x) an amendment to the Companys Certificate of Incorporation to authorize a sufficient number of shares of Common Stock to permit the full conversion of the Preferred Shares and the full exercise of all Series D Warrants and Series E
Warrants, and (y) the removal of the restriction prohibiting the exercise of certain Series D Warrants and Series E Warrants if, after giving effect to such exercise, the holder of such warrants would beneficially own in excess of 19.99% of the
Companys outstanding shares of Common Stock (the 19.99% Restriction), and (z) any and all actions contemplated in connection with the Rights Offering, as more fully described in Section 5.2.
(e) Unless the Requisite Holders previously agree in writing to waive the Companys obligations under this
Section 5.1, each Purchaser agrees to vote all shares of Common Stock beneficially owned by such Purchaser or any Affiliate of such Purchaser in favor of the Corporate Actions, at every duly called meeting of the stockholders of the
Company at which such matters are duly considered and at every adjournment or postponement thereof.
5.2 Rights Offering. The
Company shall have the right to conduct a rights offering (the Rights Offering) providing the shareholders of the Company (other than the Purchasers) the non-transferable right to purchase, at the Conversion Price (as defined in
the Certificate of Designations), shares of Common Stock; provided, that (i) the Rights Offering shall result in no more than $10,000,000 in gross proceeds to the Company and (ii) no shareholder shall receive such rights or
otherwise be entitled to purchase in the Rights Offering shares of Common Stock in excess of such shareholders pro rata ownership of the outstanding shares of Common Stock (relative to the total outstanding shares of Common Stock, excluding
those held by the Purchasers). Nothing herein or in any other Transaction Document shall obligate the Company to allow any Purchaser to participate in the Rights Offering, and each Purchaser irrevocably waives any right it and its Affiliates
may have in participating in the Rights Offering.
22
5.3 Transfer Restrictions.
(a) The Securities may only be disposed of in compliance with state and federal securities laws. In connection with any
transfer of Securities other than pursuant to an effective registration statement under the Securities Act or Rule 144, to the Company or to an Affiliate of a Purchaser or in connection with a pledge as contemplated in Section 5.3(b),
the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the
Company, to the effect that such transfer does not require registration of such transferred Securities under the Securities Act.
(b) The Purchasers agree to the imprinting, so long as is required by this Section 5.3, of a legend on any of the
Securities in the following form:
THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE SECURITIES ACT), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY MAY BE
PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT.
(c) Subject to the requirements in this Section 5.3(c),
certificates evidencing the Securities shall not contain any legend (including the legend set forth in Section 5.3(b) hereof), (i) while a registration statement (including the Registration Statement) covering the resale of such
Security is effective under the Securities Act, (ii) following any sale of such Securities pursuant to Rule 144, (iii) if such Securities are eligible for sale under Rule 144, without the requirement for the Company to be in compliance
with the current public information required under Rule 144 as to such securities and without volume or manner-of-sale restrictions, or (iv) if such legend is not required under applicable requirements of the Securities Act (including judicial
interpretations and pronouncements issued by the staff of the Commission). Upon the request of any Purchaser, the Company shall cause its counsel to issue a legal opinion to the Transfer Agent (if required by the Transfer Agent to effect the removal
of the legend hereunder) with respect to the removal of the restrictive legends on the Securities. If all or any portion of a Warrant is exercised at a time when there is an effective registration statement to cover the resale of the Warrant Shares,
or if such Warrant Shares may be sold under Rule 144 and the Company is then in compliance with the current public information required under Rule 144, or if the Warrant Shares may be sold under Rule
23
144 without the requirement for the Company to be in compliance with the current public information required under Rule 144 as to such Warrant Shares or if such legend is not otherwise required
under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission) then such Warrant Shares shall be issued free of all legends. The Company agrees that following the
Effective Date or at such time as such legend is no longer required under this Section 5.3(c), it will, no later than three Trading Days following the delivery by a Purchaser to the Company (or to the Transfer Agent, with notice to the
Company) of a certificate representing the Securities issued with a restrictive legend, together with any representation letter reasonably requested by the Company or the Transfer Agent, deliver or cause to be delivered to such Purchaser a
certificate representing such Securities that is free from all restrictive and other legends. The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge the restrictions on transfer set forth in this
Section 5.3. The Company shall provide reasonable assistance to the Purchasers in order to provide that certificates for Securities subject to legend removal hereunder are transmitted by the Transfer Agent to the Purchaser by crediting
the account of the Purchasers prime broker with the Depository Trust Company System as directed by such Purchaser.
5.4
Furnishing of Information; Public Information. Until the earliest of the time that (i) no Purchaser owns Securities or (ii) the Warrants have expired, the Company covenants to maintain the registration of the Common Stock under
Section 12(b) of the Exchange Act and to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act.
5.5 Integration. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security
(as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require the registration under the Securities Act of the sale of the Securities or that would be integrated
with the offer or sale of the Securities for purposes of the rules and regulations of Nasdaq such that it would require shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing of
such subsequent transaction. The Purchasers shall take no action to become a group such that any transactions contemplated by this Agreement would require shareholder approval prior to Closing.
5.6 Securities Laws Disclosure; Publicity. The Company shall (a) by 9:30 a.m. (New York City time) on the Trading Day immediately
following the date hereof, issue a press release disclosing the material terms of the transactions contemplated hereby in a form reasonably satisfactory to the Principal Purchasers, and (b) file a Current Report on Form 8-K, including the
Transaction Documents as exhibits thereto, with the Commission within the time required by the Exchange Act. The Company shall consult with the Principal Purchasers in issuing any other press releases with respect to the transactions contemplated
hereby, and the Company shall not issue any such press release nor otherwise make any such public statement without the prior consent of the Principal Purchasers (which consent shall not unreasonably be withheld or delayed) or, with respect to the
public disclosure of the identity of any Purchaser, the prior consent of such Purchaser, except if such disclosure is required by law or by the rules of the Trading Market upon which the Company securities are then traded; in which case, the Company
shall promptly provide the Purchasers with prior notice of such public statement or communication.
24
5.7 Shareholder Rights Plan. To the extent that it would impair the ability of any
Purchaser to exercise its rights under the Transaction Documents, including the right to receive any Securities or fully exercise or convert any Securities, as applicable, no claim will be made or enforced by the Company or, with the consent of the
Company, any other Person, that any Purchaser is an Acquiring Person under any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or
arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement.
5.8 Use of Proceeds. The Company shall use the net proceeds from the sale of the Securities hereunder for funding operations or
for working capital or other general corporate purposes.
5.9 Indemnification of Purchasers. Subject to the provisions of
this Section 5.9, the Company will indemnify and hold each Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such
titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers,
shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a
Purchaser Party) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys fees
and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other
Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Parties, with respect
to any of the transactions contemplated by the Transaction Documents (unless such action is based upon a breach of such Purchaser Partys representations, warranties or covenants under the Transaction Documents or any agreements or
understandings such Purchaser Parties may have with any such stockholder or any violations by such Purchaser Parties of state or federal securities laws or any conduct by such Purchaser Parties which constitutes fraud, gross negligence, willful
misconduct or malfeasance of such Purchaser Party). If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing,
and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate
in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the
Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel, a material conflict on any material issue between the position
25
of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel, and
(iv) notwithstanding the foregoing, the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel engaged by the Principal Purchasers. The Company will not be liable to any Purchaser Party under
this Agreement (y) for any settlement by a Purchaser Party effected without the Companys prior written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim,
damage or liability is attributable to any Purchaser Partys breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification
required by this Section 5.9 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained herein shall be
in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to law.
5.10 Reservation of Common Stock. Subject to the receipt of the Requisite Stockholder Approval, the Company shall reserve and continue
to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue shares of Common Stock upon the conversion of the Preferred Shares and the Warrant
Shares pursuant to any exercise of the Warrants.
5.11 Listing of Common Stock. The Company hereby agrees to use reasonable best
efforts to maintain the listing or quotation of the Common Stock on the Trading Market on which it is currently listed, and, as promptly as practicable following the Closing, subject to the Requisite Stockholder Approval, to secure the listing of
all of the Warrant Shares and shares of Common Stock issued upon the conversion of the Preferred Shares on such Trading Market, subject to official notice of issuance. The Company further agrees that if the Company applies to have the Common Stock
traded on any other Trading Market, it will then include in such application all of the Warrant Shares and shares of Common Stock issued or issuable upon the conversion of the Preferred Shares, and will take such other action as is necessary to
cause all of such shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing or quotation and trading of its Common Stock on a Trading Market
and will comply in all respects with the Companys reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Purchasers and the Company agree to cooperate in good faith, if necessary, to restructure the
transactions contemplated by the Transaction Documents such that they do not contravene the rules and regulations of Nasdaq; provided, however, that such restructuring does not impact the economic interests of the Purchasers
contemplated by the Transaction Documents. Each Purchaser agrees to provide information reasonably requested by the Company to comply with this Section 5.11 and Section 3.23.
5.12 Exchange of Warrants. Following the Requisite Stockholder Approval authorizing the removal of the 19.99% Restriction on the
exercise of certain Series D Warrants and the Series E Warrants, the Company shall promptly issue, at any such holders request, a new warrant to such holder, identical in all respects to such holders previous warrant, but for the
elimination of the 19.99% Restriction.
26
5.13 Equal Treatment of Purchasers. No consideration (including any modification of any
Transaction Document) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration is also offered to all of the parties to this Agreement. For clarification
purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not in any way be construed as
the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of Securities or otherwise.
5.14
Form D; Blue Sky Filings. The Company agrees to timely file a Form D with respect to the Securities as required under Regulation D and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action as
the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the Securities for, sale to the Purchasers at the Closing under applicable securities or Blue Sky laws of the states of the United
States, and shall provide evidence of such actions promptly upon request of any Purchaser. Each Purchaser shall provide any information reasonably requested by the Company to comply with this Section 5.14.
5.15 Acknowledgment of Dilution. The Company acknowledges that the issuance of the Securities may result in dilution of the outstanding
shares of Common Stock, which dilution may be substantial under certain market conditions. The Company further acknowledges that its obligations under the Transaction Documents, including, without limitation, its obligation to issue the Preferred
Shares and, subject to the receipt of the Requisite Stockholder Approval, the shares of Common Stock issued upon the conversion of the Preferred Shares and the Warrant Shares, in each case pursuant to the Transaction Documents, are unconditional and
absolute and not subject to any right of set off, counterclaim, delay or reduction, regardless of the effect of any such dilution or any claim the Company may have against any Purchaser and regardless of the dilutive effect that such issuance may
have on the ownership of the other stockholders of the Company.
5.16 Other Actions. Except as otherwise set forth in this
Agreement, from the date of this Agreement until the earlier to occur of the Closing or the termination of this Agreement in accordance with the terms hereof, the Company and the Purchasers shall not, and shall not permit any of their respective
Affiliates to, take, or agree or commit to take, any action that would reasonably be expected to, individually or in the aggregate, prevent, materially delay or materially impede the consummation of the transactions contemplated by this Agreement.
ARTICLE VI.
TERMINATION
6.1
Termination. The obligations of the Company, on the one hand, and the Purchasers, on the other hand, to effect the Closing shall terminate as follows:
(a) Upon the mutual written consent of the Company and the Purchasers;
(b) By the Company if any of the conditions set forth in Section 2.4(a) shall have become incapable of fulfillment, and shall not
have been waived by the Company;
27
(c) By a Purchaser (with respect to itself only) if any of the conditions set forth in
Section 2.4(b) shall have become incapable of fulfillment, and shall not have been waived by such Purchaser; or
(d) By either
the Company or any Purchaser (with respect to itself only) if the Closing has not occurred on or prior to March 16, 2015;
provided, however, that,
except in the case of clause (a) above, the party seeking to terminate its obligation to effect the Closing shall not then be in breach of any of its representations, warranties, covenants or agreements contained in this Agreement or the other
Transaction Documents if such breach has resulted in the circumstances giving rise to such partys seeking to terminate its obligation to effect the Closing.
6.2 Notice of Termination; Effect of Termination. In the event of termination by the Company or any Purchaser of its obligations to
effect the Closing pursuant to this ARTICLE VI, written notice thereof shall forthwith be given to the other Purchasers by the Company and the other Purchasers shall have the right to terminate their obligations to effect the Closing upon
written notice to the Company and the other Purchasers. Nothing in this ARTICLE VI shall be deemed to release any party from any liability for any breach by such party of the terms and provisions of this Agreement or the other Transaction
Documents or to impair the right of any party to compel specific performance by any other party of its obligations under this Agreement or the other Transaction Documents.
ARTICLE VII.
MISCELLANEOUS
7.1 Fees
and Expenses. The parties hereto shall pay their own costs and expenses in connection herewith, except that the Company shall pay the reasonable fees and expenses of Willkie Farr & Gallagher LLP, regardless of whether the transactions
contemplated hereby are consummated; it being understood that Willkie Farr & Gallagher LLP has only rendered legal advice to Oracle and not to the Company or any other Purchaser in connection with the transactions contemplated hereby, and
that each of the Company and each Purchaser has relied for such matters on the advice of its own respective counsel. Such expenses shall be paid upon demand. The Company shall reimburse the Purchasers upon demand for all reasonable out-of-pocket
expenses incurred by the Purchasers, but other than as set forth above in this Section 7.1 relating to Willkie Farr & Gallagher LLP, shall not reimburse for attorneys fees.
7.2 Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of
the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and
schedules.
7.3 Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder
shall be in writing and shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number set forth on the signature pages attached hereto at
or prior to
28
5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number
set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2nd) Trading Day
following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as
follows:
(i) if to the Company, to Hansen Medical, Inc., 800 East Middlefield Road, Mountain View, CA 94043 (facsimile: 650-404-5901),
Attention: Chief Financial Officer, with a copy to Sidley Austin LLP, 555 California Street, 20th Floor, San Francisco, California 94104 (facsimile: 415-772-7400), Attention: Sharon
R. Flanagan; and
(ii) if to the Purchasers, to their respective addresses as set forth on Exhibit A attached hereto, with a copy to
Willkie Farr & Gallagher LLP, 787 Seventh Avenue, New York, New York 10019 (facsimile 212-728-9592), Attention: Jeffrey S. Hochman.
7.4 Amendments; Waivers. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument
signed, in the case of an amendment, by the Company and the Principal Purchasers or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought. No waiver of any default with respect to any provision,
condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any
party to exercise any right hereunder in any manner impair the exercise of any such right.
7.5 Headings. The headings herein are
for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.
7.6 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser. With the consent of the Company which will not be unreasonably withheld, any Purchaser may
assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities, provided, that a Purchaser may assign any or all rights under this Agreement to an Affiliate of such Purchaser
without the consent of the Company, provided, further that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of the Transaction Documents that apply to the Purchasers.
7.7 No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 5.9.
7.8 Governing Law; Jurisdiction. This Agreement shall be governed by, and construed in accordance with, the internal laws of the State
of Delaware without regard to the
29
choice of law principles thereof. Each of the parties hereto irrevocably submits to the exclusive jurisdiction of the state and federal courts located in the State of Delaware for the purpose of
any suit, action, proceeding or judgment relating to or arising out of this Agreement and the transactions contemplated hereby. Service of process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in
the world by the same methods as are specified for the giving of notices under this Agreement. Each of the parties hereto irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in
such court. Each party hereto irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court
has been brought in an inconvenient forum.
7.9 WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY
JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.
7.10 Survival. The representations and warranties contained herein shall survive the Closing and the delivery of the
Securities.
7.11 Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be
considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any
signature is delivered by facsimile transmission or by e-mail delivery of a .pdf format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the
same force and effect as if such facsimile or .pdf signature page were an original thereof.
7.12 Severability. If any
term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain
in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as
that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including
any of such that may be hereafter declared invalid, illegal, void or unenforceable.
7.13 Rescission and Withdrawal Right.
Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and the
Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or
election in whole or in part without prejudice to its future actions and rights.
30
7.14 Remedies. In addition to being entitled to exercise all rights provided herein or
granted by law, including recovery of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss
incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agree to waive and not to assert in any action for specific performance of any such obligation the defense that a remedy at law would be adequate.
7.15 Independent Nature of Purchasers Obligations and Rights. The obligations of each Purchaser under any Transaction Document
are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing
contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant hereof or thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or
create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently protect and
enforce its rights, including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for
such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. The Company has elected to provide all Purchasers with the same terms and Transaction Documents for the
convenience of the Company and not because it was required or requested to do so by any of the Purchasers.
(Signature Pages Follow)
31
IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly
executed by their respective authorized signatories as of the date first indicated above.
|
|
|
HANSEN MEDICAL, INC. |
|
|
By: |
|
/s/ Christopher P. Lowe |
Name: |
|
Christopher P. Lowe |
Title: |
|
Interim Chief Financial Officer |
[Purchase Agreement
Signature Page]
|
|
|
SCHULER FAMILY FOUNDATION |
|
|
By: |
|
/s/ Jack W. Schuler |
Name: |
|
Jack W. Schuler |
Title: |
|
Trustee |
[Purchase Agreement
Signature Page]
|
|
|
ORACLE PARTNERS, LP |
|
|
By: |
|
/s/ Larry N. Feinberg |
Name: |
|
Larry N. Feinberg |
Title: |
|
Managing Member of General Partner |
[Purchase Agreement
Signature Page]
|
|
|
ORACLE TEN FUND MASTER, LP |
|
|
By: |
|
/s/ Larry N. Feinberg |
Name: |
|
Larry N. Feinberg |
Title: |
|
Managing Member of General Partner |
[Purchase Agreement
Signature Page]
|
|
|
ORACLE INSTITUTIONAL PARTNERS, LP |
|
|
By: |
|
/s/ Larry N. Feinberg |
Name: |
|
Larry N. Feinberg |
Title: |
|
Managing Member of General Partner |
[Purchase Agreement
Signature Page]
|
|
|
FEINBERG FAMILY TRUST |
|
|
By: |
|
/s/ Adam Usdan |
Name: |
|
Adam Usdan |
Title: |
|
Trustee |
[Purchase Agreement
Signature Page]
|
/s/ Matthew Strobeck |
Name: Matthew Strobeck |
[Purchase Agreement
Signature Page]
|
|
|
BIRCHVIEW FUND LLC |
|
|
By: |
|
/s/ Matthew Strobeck |
Name: |
|
Matthew Strobeck |
Title: |
|
Managing Member |
[Purchase Agreement
Signature Page]
|
/s/ Vaughn Bryson |
Name: Vaughn Bryson |
[Purchase Agreement
Signature Page]
|
/s/ Garo Armen |
Name: Garo Armen |
[Purchase Agreement
Signature Page]
|
|
|
KENNEDY PRIVATE EQUITY, LLC |
|
|
By: |
|
Kennedy Advisors LLC, its manager |
|
|
By: |
|
/s/ Lawrence T. Kennedy, Jr. |
Name: |
|
Lawrence T. Kennedy, Jr. |
Title: |
|
Vice President |
[Purchase Agreement
Signature Page]
|
|
|
THE JOHN AND CHRISTINE BROWNER FAMILY IRREVOCABLE TRUST |
|
|
By: |
|
/s/ Christine K. Browner |
Name: |
|
Christine K. Browner |
Title: |
|
Trust Advisor |
[Purchase Agreement
Signature Page]
|
|
|
CENTRAL PARK ASSOCIATES, LLC |
|
|
By: |
|
/s/ Lawrence T. Kennedy |
Name: |
|
Lawrence T. Kennedy |
Title: |
|
Managing Member |
[Purchase Agreement
Signature Page]
|
|
|
MARTHA K. LORD REVOCABLE TRUST |
|
|
By: |
|
/s/ Martha K. Lord |
Name: |
|
Martha K. Lord |
Title: |
|
Trustee |
[Purchase Agreement
Signature Page]
|
|
|
PETER M. KENNEDY REVOCABLE TRUST |
|
|
By: |
|
/s/ Peter M. Kennedy |
Name: |
|
Peter M. Kennedy |
Title: |
|
Trustee |
[Purchase Agreement
Signature Page]
|
|
|
DENISON ASSOCIATES, LLC |
|
|
By: |
|
/s/ Peter M. Kennedy |
Name: |
|
Peter M. Kennedy |
Title: |
|
Managing Member |
[Purchase Agreement
Signature Page]
|
|
|
FREDERIC HUTCHINS MOLL REVOCABLE TRUST |
|
|
By: |
|
/s/ Frederic H. Moll, M.D. |
Name: |
|
Frederic H. Moll, M.D. |
Title: |
|
Executor |
[Purchase Agreement
Signature Page]
EXHIBIT A
SCHEDULE OF PURCHASERS
|
|
|
|
|
|
|
|
|
Purchaser |
|
Investment Amount |
|
|
Preferred Shares and Warrants Purchased |
|
Series D Warrants Exchanged |
Schuler Family Foundation |
|
|
$15,000,050 |
|
|
Preferred Shares 23,077
Series E Warrants 23,077,000 |
|
Series D Warrants 2,694,673 |
|
|
|
|
Oracle Partners, LP |
|
|
$8,000,200 |
|
|
Preferred Shares 12,308
Series E Warrants 12,308,000 |
|
Series D Warrants 1,431,983 |
|
|
|
|
Oracle Ten Fund Master, LP |
|
|
$2,499,900 |
|
|
Preferred Shares 3,846
Series E Warrants 3,846,000 |
|
Series D Warrants 360,350 |
|
|
|
|
Oracle Institutional Partners, LP |
|
|
$1,500,200 |
|
|
Preferred Shares 2,308
Series E Warrants 2,308,000 |
|
Series D Warrants 200,712 |
|
|
|
|
Feinberg Family Trust |
|
|
$1,149,850 |
|
|
Preferred Shares 1,769
Series E Warrants 1,769,000 |
|
Series D Warrants 400,000 |
|
|
|
|
Matthew Strobeck |
|
|
$499,850 |
|
|
Preferred Shares 769
Series E Warrants 769,000 |
|
Series D Warrants N/A |
|
|
|
|
|
|
|
|
|
Purchaser |
|
Investment Amount |
|
|
Preferred Shares and Warrants Purchased |
|
Series D Warrants Exchanged |
|
|
|
|
Birchview Fund LLC |
|
|
$999,700 |
|
|
Preferred Shares 1,538
Series E Warrants 1,538,000 |
|
Series D Warrants N/A |
|
|
|
|
Vaughn Bryson |
|
|
$100,100 |
|
|
Preferred Shares 154
Series E Warrants 154,000 |
|
Series D Warrants N/A |
|
|
|
|
Garo Armen |
|
|
$200,200 |
|
|
Preferred Shares 308
Series E Warrants 308,000 |
|
Series D Warrants N/A |
|
|
|
|
Kennedy Private Equity, LLC |
|
|
$2,000,050 |
|
|
Preferred Shares 3,077 Series E
Warrants 3,077,000 |
|
Series D Warrants N/A |
|
|
|
|
The John and Christine Browner Family Irrevocable Trust |
|
|
$250,250 |
|
|
Preferred Shares 385 Series E
Warrants 385,000 |
|
Series D Warrants N/A |
|
|
|
|
Central Park Associates, LLC |
|
|
$999,700 |
|
|
Preferred Shares 1,538 Series E
Warrants 1,538,000 |
|
Series D Warrants N/A |
|
|
|
|
Martha K. Lord Revocable Trust |
|
|
$999,700 |
|
|
Preferred Shares 1,538 Series E
Warrants 1,538,000 |
|
Series D Warrants N/A |
|
|
|
|
Peter M. Kennedy Revocable Trust |
|
|
$200,200 |
|
|
Preferred Shares 308 Series E
Warrants 308,000 |
|
Series D Warrants N/A |
|
|
|
|
Denison Associates, LLC |
|
|
$100,100 |
|
|
Preferred Shares 154 Series E
Warrants 154,000 |
|
Series D Warrants N/A |
|
|
|
|
|
|
|
|
|
Purchaser |
|
Investment Amount |
|
|
Preferred Shares and Warrants Purchased |
|
Series D Warrants Exchanged |
|
|
|
|
Frederic Hutchins Moll Revocable Trust |
|
|
$499,850 |
|
|
Preferred Shares 769
Series E Warrants 769,000 |
|
Series D Warrants N/A |
EXHIBIT B
FORM OF CERTIFICATE OF DESIGNATIONS
EXHIBIT C
FORM OF SECOND AMENDED AND RESTATED INVESTOR RIGHTS
AGREEMENT
EXHIBIT D
FORM OF WARRANT
Exhibit 4.2
Execution Version
NEITHER THIS WARRANT,
NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT (COLLECTIVELY, THE SECURITIES), HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE SECURITIES ACT), OR UNDER ANY STATE SECURITIES OR
BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE OFFERED, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES OR BLUE
SKY LAWS, PURSUANT TO REGISTRATION OR QUALIFICATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THE SECURITIES MAY REQUIRE
AN OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER IS IN COMPLIANCE WITH THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES OR BLUE SKY LAWS.
HANSEN MEDICAL, INC.
SERIES E WARRANT
|
|
|
Warrant No. E-[] |
|
Date of Issuance: March 11, 2015 |
Hansen Medical, Inc., a Delaware corporation (the Company), hereby certifies that, for
value received, [], a [], or its registered assign (the Holder), is entitled to
purchase from the Company [] shares (as adjusted from time to time as provided in Section 12 [but subject to Section 6(b)]1) of common stock, par value $0.0001 per share, of the Company (the Common Stock) (each such share, a Warrant Share and all such shares, the Warrant
Shares), at an exercise price determined pursuant to Section 3 (the Exercise Price), at any time and from time to time from and after the date hereof through and including the date that is two years following
the date of issuance set forth above (the Expiration Date), and subject to the following terms and conditions:
1.
Securities Purchase Agreement. This Series E Warrant (this Warrant) is issued by the Company in connection with that certain Securities Purchase Agreement, entered into on March 9, 2015 (the Purchase
Agreement), by and among the Company and the Holder and certain other Purchasers named therein, and is subject to, and the Company and the Holder shall be bound by, all the applicable terms, conditions and provisions of the Purchase
Agreement.
2. Definitions. In addition to the terms defined elsewhere in this Warrant, capitalized terms that are not otherwise
defined herein shall have the meanings assigned to such terms in the Purchase Agreement.
3. Exercise Price. This Warrant may be
exercised for a price per Warrant Share equal to $0.975, or such lesser price equal to a fifty percent premium on the trailing volume-weighted average share price per share of Common Stock on Nasdaq for the ten trading days ending on the date prior
to the date on which the Requisite Stockholder Approval is obtained (or, if such approval is not necessary pursuant to the Nasdaq listing rules, the earlier of the date on which this Warrant is exercised or December 31, 2015), subject to
adjustment from time to time pursuant to Section 12 (the Exercise Price). The Company shall promptly notify the Holder in writing of any adjustments to the Exercise Price effectuated in accordance with this
Section 3 upon obtaining the Requisite Stockholder Approval contemplated by the Purchase Agreement.
1 |
To be included for affiliated entities of each of Messrs. Feinberg and Schuler. |
4. Registration of Warrant. The Company shall register this Warrant, upon records to be
maintained by the Company for that purpose (the Warrant Register), in the name of the record Holder hereof from time to time. The Company may deem and treat the Holder of this Warrant as the absolute owner hereof for the purpose
of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.
5.
Transfer of Warrant. Subject to the Holders appropriate compliance with the restrictive legend on this Warrant, the Company shall register the transfer of any portion of this Warrant in the Warrant Register, upon surrender of this
Warrant, with the Form of Assignment substantially in the form attached hereto as Attachment B duly completed and signed, to the Company at its address specified herein. Upon any such registration or transfer, a new Warrant to purchase
Common Stock, in substantially the form of this Warrant (any such new Warrant, a New Warrant), evidencing the portion of this Warrant so transferred shall be issued to the transferee and a New Warrant evidencing the remaining
portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations of a
holder of a Warrant.
6. Exercise and Duration of Warrants.
(a) This Warrant shall be exercisable by the registered Holder at any time and from time to time on or after the date hereof to and including
the Expiration Date. At 6:30 p.m., New York City time, on the Expiration Date, the portion of this Warrant not exercised prior thereto shall be and become void and of no value. The Company may not call or redeem all or any portion of this Warrant
without the prior written consent of the Holder.
(b) [Notwithstanding anything contained herein to the contrary, prior to any Requisite
Stockholder Approval authorizing any action otherwise (including the elimination of restrictions imposed by this Section 6(b)), the Company shall not effect any exercise of this Warrant, and the Holder shall not have the right to
exercise any portion of this Warrant to the extent that after giving effect to such issuance after exercise as set forth on the applicable notice of exercise, the Holder (together with the Holders affiliates, and any other persons acting as a
group together with the Holder or any of the Holders affiliates), would beneficially own in excess of 19.99% of the outstanding shares of Common Stock. For purposes of the foregoing sentence, the number of shares of Common Stock beneficially
owned by the Holder and its affiliates shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which
would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any other
securities of the Company (including, without limitation, any other securities of the Company or its subsidiaries which would entitle the holder thereof to acquire at any time shares of Common Stock) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by the Holder or any of its affiliates. Except as set forth in the preceding sentence, for purposes of this Section 6(b), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act), and the rules and regulations promulgated thereunder. In addition, for purposes of this Section 6(b),
group has the meaning set forth in Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. To the extent that the limitation contained in this Section 6(b) applies, the determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any affiliates) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a
notice of exercise shall be deemed to be the Holders determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any affiliates) and of which portion of this Warrant is
-2-
exercisable. For purposes of this Section 6(b), in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common
Stock as reflected in (i) the Companys most recent Form 10-K, Form 10-Q, Current Report on Form 8-K or other public filing with the Commission, as the case may be, (ii) a more recent public announcement by the Company or (iii) a
more recent notice by the Company or the Companys transfer agent to the Holder setting forth the number of shares of Common Stock then outstanding. Upon the request of the Holder, the Company shall promptly, and in any event within one
trading day of such request, confirm to the Holder the number shares of Common Stock then outstanding. Following the Requisite Stockholder Approval, and upon surrender of this Warrant to the Company, the Company shall promptly issue, at the
Holders request, a New Warrant to such Holder, identical in all respects to such Holders previous Warrant, but for the elimination of this Section 6(b).]2
7. Delivery of Warrant Shares.
(a) To effect conversions hereunder, the Holder shall not be required to physically surrender this Warrant unless the total number of Warrant
Shares (as adjusted from time to time as provided in Section 12) represented by this Warrant is being exercised. Upon delivery of an Exercise Notice substantially in the form attached hereto as Attachment A (an
Exercise Notice) to the Company at its address for notice determined as set forth herein, and upon payment of the applicable Exercise Price multiplied by the number of Warrant Shares that the Holder intends to purchase hereunder,
the Company shall promptly (but in no event later than five trading days after the Date of Exercise (as defined below)) issue and deliver, or cause its transfer agent to issue and deliver, to the Holder a certificate for the Warrant Shares issuable
upon such exercise registered in the name of the Holder or its designee. A Date of Exercise means the date on which the Holder shall have delivered to the Company: (i) an Exercise Notice, appropriately completed and duly
signed, and (ii) payment of the Exercise Price (by certified or official bank check, intra-bank account transfer or wire transfer) for the number of Warrant Shares so indicated by the Holder to be purchased.
(b) If by the fifth trading day after a Date of Exercise the Company fails to deliver the required number of Warrant Shares in the manner
required pursuant to Section 7(a), the Holder will have the right to rescind such exercise.
(c) The Companys
obligations to issue and deliver Warrant Shares in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof,
the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company
or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares.
Nothing herein shall limit a Holders right to pursue any other remedies available to it hereunder, at law or in equity, including a decree of specific performance and/or injunctive relief with respect to the Companys failure to timely
deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.
8.
Charges, Taxes and Expenses. Issuance and delivery of certificated or uncertificated shares of Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, withholding tax, transfer
agent fee, or other incidental tax or expense in respect of the issuance of such shares, all of which taxes and expenses shall be paid by the Company; provided,
2 |
Section 6(b) to be included for affiliated entities of each of Messrs. Feinberg and Schuler.
|
-3-
however, that the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or
Warrants in a name other than that of the Holder. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.
9. Replacement of Warrant. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in
exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a new Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction and customary and
reasonable indemnity (which shall not include a surety bond), if requested. Applicants for a new Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs
as the Company may prescribe. If a new Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver this mutilated Warrant to the Company as a condition precedent to the Companys obligation to issue the new
Warrant.
10. Reservation of Warrant Shares. Subject to the Company obtaining the Requisite Stockholder Approval in respect of the
following, the Company covenants that it will at all times reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon
exercise of this Warrant as herein provided, the number of Warrant Shares which are then issuable and deliverable upon the exercise of this entire Warrant, free from liens or any other contingent purchase rights of persons other than the Holder
(taking into account the adjustments and restrictions of Section 12). The Company covenants and warrants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in
accordance with the terms hereof, be duly and validly authorized, issued and fully paid and non-assessable.
11. Notice of Certain
Corporate Action. In case the Company shall propose (a) to offer to the holders of its Common Stock rights to subscribe for or to purchase any shares of Common Stock or shares of stock of any class or any other securities, rights or
options, or (b) to effect any reclassification of its Common Stock (other than a reclassification involving only the subdivision, or combination, of outstanding shares of Common Stock), or (c) to effect any capital reorganization, or
(d) to effect any Fundamental Transaction (as defined below), or (e) to effect the liquidation, dissolution or winding up of the Company or (f) to offer to the holders generally of its Common Stock the right to have their shares of
Common Stock repurchased or redeemed or otherwise acquired by the Company, or (g) to take any other action which would require the adjustment of the Exercise Price and/or the number of Warrant Shares issuable upon exercise of this Warrant, then
in each such case (but without limiting the provisions of Section 12), the Company shall give to the Holder a notice of such proposed action, which shall specify the date on which a record is to be taken for purposes of such dividend,
distribution of offer of rights, or the date on which such reclassification, reorganization, Fundamental Transaction, liquidation, dissolution, or winding up is to take place and the date of participation therein by the holders of Common Stock, if
any such date is to be fixed and shall also set forth such facts with respect thereto as shall be reasonably necessary to indicate the effect of such action on the Common Stock; provided, that no such notice hereunder shall be required
in connection with the Rights Offering. Such notice shall be so given at least ten Business Days prior to the record date for determining holders of the Common Stock for purposes of participating in or voting on such action, or at least ten Business
Days prior to the date of the taking of such proposed action or the date of participation therein by the holders of Common Stock, whichever shall be the earlier. Such notice shall specify, in the case of any subscription or repurchase rights, the
date on which the holders of Common Stock shall be entitled thereto, or the date on which the holders of Common Stock shall be entitled to exchange their Common Stock for securities or other property deliverable upon any reorganization,
reclassification, Fundamental Transaction or other action, as the case may be. Such notice shall also state whether the action in question or the record date is subject to the
-4-
effectiveness of a registration statement under the Securities Act or to a favorable vote of security holders, if either is required, and the adjustment in Exercise Price and/or number of Warrant
Shares issuable upon exercise of this Warrant as a result of such reorganization, reclassification, Fundamental Transaction or other action, to the extent then determinable. No such notice shall be given if the Company reasonably determines that the
giving of such notice would require disclosure of material information which the Company has a bona fide purpose for preserving as confidential or the disclosure of which would not be in the best interests of the Company.
12. Certain Adjustments. The number of Warrant Shares issuable upon exercise of this Warrant is subject to adjustment from time to time
as set forth in this Section 12.
(a) Stock Dividends and Splits. If the Company, at any time while this Warrant is
outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall
not include any shares of Common Stock issued by the Company upon exercise of any Warrants), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split)
outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of Common Stock any shares of capital stock of the Company; then in each such case (A) the Exercise Price will be adjusted by
multiplying the Exercise Price then in effect by a fraction, the numerator of which equals the number of shares of Common Stock outstanding immediately prior to such event (excluding treasury shares, if any), and the denominator of which equals the
number of shares of Common Stock outstanding immediately after such event (excluding treasury shares, if any), and (B) the number of Warrant Shares issuable hereunder shall be concurrently adjusted by multiplying such number by the reciprocal
of such fraction. Such adjustments will take effect (i) if a record date shall have been fixed for determining the stockholders or security holders, as applicable, of the Company entitled to receive such dividend, distribution or issuance by
reclassification, as the case may be, immediately after such record date, (ii) otherwise, immediately after the effective date of such dividend, distribution, subdivision, combination, or issuance by reclassification, as the case may be.
(b) Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
a series of related transactions, (A) effects any merger or consolidation of the Company with or into another Person, (B) effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all
of its assets, (C) effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or
property (except for issuances by reclassification contemplated by Section 12(a)(iv)), or (D) consummates a stock or share purchase agreement or other business combination (including a reorganization, recapitalization, spin-off or
scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than fifty percent of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or group
making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination), or (ii) any, direct or indirect, purchase offer, tender offer or exchange offer
(whether by the Company or another Person or group of Persons) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property (each transaction or series of
transactions referred to in clause (i) or (ii) above, a Fundamental Transaction); then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, (1) the number of shares of common stock of the successor or acquiring corporation or, if it is the surviving corporation, of the Company, and
(2) any additional consideration (the Alternate Consideration) receivable as a result of
-5-
such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction. For purposes of any such
exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount and components of Alternate Consideration issuable in respect of one share of Common Stock in such
Fundamental Transaction, and the Board of Directors shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration (substituting
the most appropriate market-based measure for the Trading Market in determining the daily VWAP (as defined below) from time to time for each component of the Alternate Consideration or, if no market-based measure is reasonably available for any such
component, fixing the daily VWAP of such component at the value determined by such apportionment, but subject to further adjustment as provided in this Section 12). If holders of Common Stock are given any choice as to the securities,
cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. To the extent
necessary to effectuate the foregoing provisions, any successor to the Company or surviving entity in such Fundamental Transaction shall issue to the Holder a new warrant of like tenor to this Warrant but adjusted to be consistent with the foregoing
provisions and evidencing the Holders right to exercise such warrant for the appropriate number of shares of capital stock and Alternate Consideration, if any, in exchange for this Warrant. The Company shall ensure that the terms of any
agreement pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this Section 12(b) and ensuring that this Warrant (or any such
replacement security) will be similarly adjusted upon any subsequent transaction or series of related transactions analogous to a Fundamental Transaction. VWAP means, for any date, the price determined by the first of the
following clauses that applies: (A) if the Common Stock is then listed or quoted on a trading market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the principal trading market on
which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a trading day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (B) if prices for the Common Stock are then reported in the Pink
Sheets published by Pink OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported during trading hours, or (C) in all
other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Companys Board of Directors and reasonably acceptable to the Principal Holders, the fees and expenses of
which shall be paid by the Company.
(c) Notice of Adjustment. Upon any adjustment of the Exercise Price, and from time to time
upon the request of the Holder, the Company shall furnish to the Holder the Exercise Price resulting from such adjustment or otherwise in effect and the number of Warrant Shares then available for purchase under this Warrant, setting forth in
reasonable detail the method of calculation and the facts upon which such calculation is based.
13. No Fractional Shares. No
fractional shares of Common Stock will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares which would otherwise be issuable, the Company shall pay the Holder an amount of cash equal to the product of such
fraction multiplied by the closing price of one share of Common Stock as reported on the principal trading market for the Common Stock on the Date of Exercise.
14. No Impairment. The Company shall not by any action including, without limitation, amending its Certificate of Incorporation, any
reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but shall at all times in
good faith assist in the
-6-
carrying out of all such terms and in the taking of all such action, as may be necessary or appropriate to protect the rights of the Holder against impairment. Without limiting the generality of
the foregoing, the Company shall take all such action as may be necessary or appropriate in order that the Company may validly issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant at the then Exercise Price
therefor.
15. No Rights as a Stockholder; Notice to Holder. Nothing contained in this Warrant shall be construed as conferring
upon the Holder the right to vote or to consent or to receive notice as a stockholder in respect of any meeting of stockholders for the election of directors of the Company or any other matter, or any rights whatsoever as a stockholder of the
Company.
16. Warrant Agent. The Company shall serve as warrant agent under this Warrant. Upon thirty days notice to the
Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or
any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or stockholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor
warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holders last address as shown on the Warrant Register.
17. Miscellaneous.
(a)
Notices. Any and all notices or other communications or deliveries hereunder (including any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or
communication is delivered via facsimile at the facsimile number pursuant to this Section 17(a) prior to 5:30 p.m. (New York City time) on a trading day, (ii) the next trading day after the date of transmission, if such notice or
communication is delivered via facsimile at the facsimile number specified pursuant to this Section 17(a) on a day that is not a trading day or later than 5:30 p.m. (New York City time) on any trading day, (iii) the second trading
day following the date of mailing, if sent by nationally recognized overnight courier service to the street address specified pursuant to this Section 17(a), or (iv) upon actual receipt by the party to whom such notice is required
to be given. The addresses for such communications shall be as follows:
(i) if to the Company, to:
Hansen Medical, Inc.
800 East
Middlefield Road
Mountain View, CA 94043
Attn: Chief Financial Officer
Facsimile: (650) 404-5901
with a copy to (which shall not constitute notice to the Company):
Sidley Austin LLP
555 California Street, 20th Floor
San Francisco, CA 94104
Attn:
Sharon R. Flanagan
Facsimile: (415) 772-7400
-7-
(ii) if to the Holder, to the address, facsimile number or email or street
address appearing on the Warrant Register (which shall initially be the facsimile number and email and street address set forth for the initial Holder in the Purchase Agreement);
or to such other address, facsimile number or email address as the Company or the Holder may provide to the other in accordance with this
Section 17(a).
(b) Assignment. The rights and obligations of the Company and the Holder shall be binding upon, and
inure to the benefit of, the successors, assigns, heirs, administrators and transferees of the parties. The Company shall not have the right directly or indirectly to assign or transfer this Warrant without the prior written consent of the Holder,
which may be withheld in the Holders sole discretion, or as part of a Fundamental Transaction.
(c) No Third Party
Beneficiaries. Nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant.
(d) Amendments; Waiver. This Warrant may be amended only in writing signed by the Company and each of the Principal Holders (as defined
below), and any amendment so effected shall amend each Warrant issued pursuant to the Purchase Agreement and be binding upon each holder of such Warrants (provided, however, that any such amendment that adversely affects any the Holder
in a manner that does not apply uniformly to all holders of such Warrants shall require the written consent of such adversely affected Holder). Any provision of this Warrant may be waived, but only if in writing by the party against whom enforcement
of any such waiver is sought. No waiver of any default with respect to any provision, condition or requirement of this Warrant shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other
provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right. For purposes of this Warrant, Principal Holders shall
mean Oracle Partners, LP, Oracle Institutional Partners, LP, Oracle Ten Fund Master, LP and the Schuler Family Foundation.
(e)
Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to principles of conflict of laws.
(f) Severability. If one or more provisions of this Warrant are held to be unenforceable under applicable law in any respect, such
provision shall be excluded from this Warrant and the balance of this Warrant shall be construed and interpreted as if such provision were so excluded and shall be enforceable in accordance with its remaining terms.
[Remainder of Page Intentionally Left Blank; Signature Page Follows]
-8-
IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized
officer as of the date first indicated above.
|
|
|
HANSEN MEDICAL, INC., a Delaware corporation |
|
|
By: |
|
|
[Signature Page Warrant]
ATTACHMENT A
EXERCISE NOTICE
To Hansen Medical, Inc.:
The undersigned hereby irrevocably elects to purchase shares (the Shares) of common stock, par value $0.0001 per share
(Common Stock), of Hansen Medical, Inc., a Delaware corporation, pursuant to Warrant No. E- , originally issued on March 11, 2015 (the
Warrant). The undersigned elects to utilize the following manner of exercise:
|
|
|
|
|
|
|
Shares: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Full Exercise of Warrant |
|
|
|
|
|
|
Partial Exercise of Warrant (in the amount of Shares) |
|
|
|
Exercise Price: |
|
$ |
|
|
|
|
|
Manner of Exercise: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Certified or Official Bank Check |
|
|
|
|
|
|
Intra-Bank Account Transfer |
|
|
|
|
|
|
Wire Transfer |
[Please issue a new Warrant for the unexercised portion of the attached Warrant in the name of the
[undersigned]/[the undersigneds nominee as is specified below].]
|
|
|
Date: |
|
|
|
|
Full Name of Holder*: |
|
|
|
|
Signature of Holder or Authorized Representative: |
|
|
|
|
Name and Title of Authorized Representative: |
|
|
|
|
Additional Signature of Holder (if jointly held): |
|
|
|
|
Social Security or Tax Identification Number: |
|
|
|
|
Address of Holder: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Full Name of Nominee of
Holder: |
|
|
|
|
Address of Nominee of
Holder: |
|
|
|
|
|
|
|
|
|
|
|
|
* |
Must conform in all respects to name of holder as specified on the face of the Warrant. |
ATTACHMENT B
FORM OF ASSIGNMENT
[To
be completed and signed only upon transfer of Warrant]
FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers
unto the right represented by the attached Series E Warrant to purchase
shares of Common Stock of Hansen Medical, Inc., a Delaware corporation (the Company), to which the Warrant relates and appoints
as attorney to transfer said right on the books of the Company with full power of substitution in
the premises.
|
|
|
Date: |
|
|
|
|
Full Name of Holder*: |
|
|
|
|
Signature of Holder or Authorized Representative: |
|
|
|
|
Name and Title of Authorized Representative: |
|
|
|
|
Additional Signature of Holder (if jointly held): |
|
|
|
|
Address of Holder: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Full Name of Transferee: |
|
|
|
|
Address of Transferee: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In the presence of: |
|
|
* |
Must conform in all respects to name of holder as specified on the face of the Warrant. |
Exhibit 4.3
Execution Version
SECOND
AMENDED AND RESTATED
INVESTOR RIGHTS AGREEMENT
This SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the Agreement) is made as of March 11, 2015 by and among
Hansen Medical, Inc., a corporation organized and existing under the laws of the State of Delaware (the Company), Oracle Partners, LP, Oracle Institutional Partners, LP and Oracle Ten Fund Master, LP (together,
Oracle), Schuler Family Foundation (the Schuler Family Foundation and together with Oracle, the Principal Purchasers) and the other parties whose names appear on the signature pages hereto
(collectively with the Principal Purchasers and those existing investors whose names appear on Schedule I hereto, the Purchasers).
RECITALS
WHEREAS, the Company
and the Purchasers entered into an Investor Rights Agreement, dated as of August 8, 2013 (the Original Agreement), in connection with the purchase of Common Stock and Series A Warrants, Series B Warrants and Series C Warrants
(each as defined therein) by the Purchasers, pursuant to that certain Securities Purchase Agreement, dated as of July 30, 2013 (the Initial Purchase Agreement);
WHEREAS, on August 11, 2014, the Company and the Purchasers amended and restated the Original Agreement (the Amended
Agreement) in connection with the Companys entry into that certain Exchange Agreement, dated as of July 30, 2014 (the Exchange Agreement), pursuant to which certain Purchasers (the Exchange
Warrantholders) surrendered to the Company for cancellation their Series B Warrants and Series C Warrants in exchange for Series B/C Exchange Warrants and Series D Warrants (each as defined therein);
WHEREAS, the Principal Purchasers and certain other Purchasers have agreed to purchase from the Company, and the Company has agreed to sell to
the Principal Purchasers and certain other Purchasers, 53,846 shares of the Series A Convertible Preferred Stock and Series E warrants exercisable to purchase 53,846,000 shares of Common Stock (Series E Warrants), on the terms and
subject to the conditions set forth in that certain Securities Purchase Agreement, dated as of March 9, 2015, by and among the Company and such Purchasers (Securities Purchase Agreement); and
WHEREAS, in connection with the consummation of the transactions contemplated by the Securities Purchase Agreement, and pursuant to the terms
of the Securities Purchase Agreement and the Amended Agreement, the parties desire to amend and restate the Amended Agreement upon the terms and conditions set forth herein.
NOW, THEREFORE, in consideration of the covenants and promises set forth herein, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:
AGREEMENT
1. Certain Definitions. Unless the context otherwise requires, the following terms, for all purposes of this Agreement, shall have the
meanings specified in this Section 1.
Additional Shelf Registration Statements has the meaning set forth
in Section 3.1(a).
Affiliate has the meaning set forth in Rule 12b-2 of the rules and regulations
promulgated under the Exchange Act; provided, however, that for purposes of this Agreement, the Purchasers and their Affiliates, on the one hand, and the Company and its Affiliates, on the other, shall not be deemed to be
Affiliates of one another.
Agreement has the meaning set forth in the preamble.
Allowed Delay has the meaning set forth in Section 3.1(b)(ii).
Amended Agreement has the meaning set forth in the recitals.
Blue Sky Application has the meaning set forth in Section 3.7(a).
Board means the board of directors of the Company.
Business Day means any day except any Saturday, any Sunday, any day which is a federal holiday in the United States or any
day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.
Closing Date has the meaning ascribed to such term in the Securities Purchase Agreement.
Common Stock means shares of the common stock, par value $0.0001 per share, of the Company.
Company has the meaning set forth in the preamble.
Exchange Act means the Securities Exchange Act of 1934, as amended.
Exchange Additional Shelf Registration Statement has the meaning set forth in Section 3.1(a).
Exchange Agreement has the meaning set forth in the recitals.
Exchange Registrable Securities means any Common Stock issuable upon the conversion or exercise of the Exchange Warrants,
or issued as a right, a dividend or other distribution with respect to, or in exchange for or in replacement of, any Common Stock underlying the Exchange Warrants held by the Exchange Warrantholders. Notwithstanding the foregoing, Exchange
Registrable Securities shall not include any securities of the Company sold by any person to the public either pursuant to a registration statement under the Securities Act or that is freely tradeable under Rule 144.
2
Exchange Warrantholders has the meaning set forth in the recitals.
Exchange Warrants means the Series B/C Exchange Warrants and the Series D Warrants.
FINRA means the Financial Industry Regulatory Authority.
Form S-3 means such form under the Securities Act as in effect on the date hereof or any successor or similar registration
form under the Securities Act subsequently adopted by the Commission that permits inclusion or incorporation of substantial information by reference to other documents filed by the Company with the Commission.
Free Writing Prospectus means an issuer free writing prospectus, as defined in Rule 433 under the Securities Act, relating
to an offer of Registrable Securities.
Holder means any person owning of record Registrable Securities that have not
been sold to the public or any transferee or assignee of record of such Registrable Securities to which the registration rights conferred by this Agreement have been transferred or assigned in accordance with Section 4.2 hereof.
Initial Purchase Agreement has the meaning set forth in the recitals.
Initial Shelf Registration Statement has the meaning set forth in Section 3.1(a).
Initially Registered Securities means the shares of Common Stock held by the Purchasers and the Common Stock issued or
issuable upon the conversion or exercise of any of the Series A Warrants, the Series B Warrants and the Series C Warrants then held by the Purchasers and registered by the Company under the Initial Registration Statement.
Initiating Shelf Take-Down Holder has the meaning set forth in Section 3.1(c).
Nasdaq has the meaning ascribed to such term in the Securities Purchase Agreement.
Nonparticipating Purchasers shall mean those Purchasers who are not parties to the Exchange Agreement.
Oracle has the meaning set forth in the preamble.
Original Agreement has the meaning set forth in the recitals.
Participating Holder means with respect to any registration, any Holder of Registrable Securities covered by the applicable
Registration Statement.
3
Person has the meaning ascribed to such term in the Securities Purchase
Agreement.
Principal Purchasers has the meaning set forth in the preamble.
Prospectus means the prospectus included in any Registration Statement, all amendments and supplements to such prospectus,
including pre- and post-effective amendments to such Registration Statement, and all other material incorporated by reference in such prospectus.
Purchaser has the meaning set forth in the preamble.
Purchaser Designee has the meaning set forth in Section 2(c).
Register, registered and registration refer to a registration effected by preparing
and filing a registration statement in compliance with the Securities Act, and the declaration or ordering of effectiveness of such registration statement or document.
Registrable Securities means shares of Common Stock held by the Purchasers (whether acquired prior to, on or following the
Closing Date), and any shares of Common Stock issued as (or issuable upon the conversion or exercise of any warrant, the Series A Convertible Preferred Stock or other convertible security, right or other security which is issued as) a dividend, upon
exercise or conversion, or other distribution with respect to, or in exchange for, or in replacement of, any Common Stock, warrant, the Series A Convertible Preferred Stock or other convertible security, right or other security held by the
Purchasers. Notwithstanding the foregoing, Registrable Securities shall not include any securities of the Company sold by any person to the public either pursuant to a registration statement under the Securities Act or that is freely tradeable under
Rule 144.
Registration Expenses has the meaning set forth in Section 3.3.
Registration Period means the period of time that will end on the date that is the later of (A) two (2) years
from the Closing Date, (B) the date by which all the Registrable Securities may be sold without volume or manner of sale restrictions which may be applicable to affiliates under Rule 144, or (C) the date on which all of the Registrable
Securities are sold.
Registration Statement means any registration statement of the Company that covers Registrable
Securities pursuant to the provisions of this Agreement filed with, or to be filed with, the SEC under the rules and regulations promulgated under the Securities Act, including the related Prospectus, amendments and supplements to such registration
statement, including pre- and post-effective amendments, and all exhibits and all material incorporated by reference in such registration statement.
Requisite Stockholder Approval has the meaning ascribed to it in the Securities Purchase Agreement.
4
Rule 144 means Rule 144 as promulgated by the SEC under the Securities Act, as
such rule may be amended from time to time, or any similar successor rule that may be promulgated by the SEC.
Schuler
has the meaning set forth in Section 2(a).
Schuler Family Foundation has the meaning set forth in the
preamble.
SEC or Commission means the Securities and Exchange Commission or any other federal
agency at the time administering the Securities Act.
Securities Act means the Securities Act of 1933, as amended, or
any similar successor federal statute and the rules and regulations thereunder, all as the same shall be in effect from time to time.
Securities Purchase Agreement has the meaning set forth in the recitals.
Series A Convertible Preferred Stock means the Series A Convertible Preferred Stock, par value $0.0001 per share, of the
Company.
Series E Warrants has the meaning set forth in the recitals.
Shelf Take-Down has the meaning set forth in Section 3.1(c).
Subsidiaries means each corporation, limited liability company, partnership, association, joint venture or other business
entity of which any party or any of its Affiliates owns, directly or indirectly, more than 50% of the stock or other equity interest entitled to vote on the election of the members of the board of directors or similar governing body.
Transaction Documents means this Agreement, the Securities Purchase Agreement, the Series E Warrants, the Initial Purchase
Agreement, the Exchange Agreement, the Exchange Warrants, the Unexchanged Warrants, and all exhibits and schedules thereto and hereto and any other documents or agreement executed in connection with the transactions contemplated hereunder or
thereunder, as applicable.
Unexchanged Warrants means the Series B Warrants and the Series C Warrants held by
Nonparticipating Purchasers that were not cancelled and exchanged for Series B/C Exchange Warrants and Series D Warrants pursuant to the Exchange Agreement.
2. Board Representation.
(a) In connection with the closing under the Initial Purchase Agreement and as required under the Original Agreement, the Company increased
the size of the Board by one member, and Jack W. Schuler (Schuler) was appointed to the Board as a member of the class whose initial term expires at the 2016 annual meeting of the Companys stockholders.
5
(b) The size of the Board shall initially be set at nine members.
(c) Subject to Section 2(a), the Company shall continue to cause Schuler (or, if Schuler is unavailable to continue to serve on
the Board, such other person designated by Schuler and reasonably acceptable to the Company) to be nominated by the Company to serve on the Board (such director, the Purchaser Designee) for so long as the Schuler Family Foundation
(or an Affiliate thereof) has beneficial ownership of shares of Common Stock (including the number of shares of Common Stock issuable upon the conversion or exercise of any convertible securities or warrants), in the aggregate, in an amount equal to
at least 50% of the shares of Common Stock issued to the Schuler Family Foundation pursuant to the Initial Purchase Agreement (including the number of shares of Common Stock issuable upon exercise of the warrants issued pursuant to such agreement).
In the event the Schuler Family Foundation (or an Affiliate thereof) no longer has beneficial ownership of such shares in the amount set forth in this Section 2(c), the Company may cause the Purchaser Designee to be replaced with a
nominee acceptable to the Company.
(d) The Purchaser Designee shall, when up for election, subject to the terms hereof and applicable
law, be the Companys nominee to serve on the Board and the Company shall solicit proxies for the Purchaser Designee to the same extent as it would for any of its other nominees to the Board. The Companys proxy statement for the election
of directors shall include the Purchaser Designee and the recommendation of the Board in favor of election of the Purchaser Designee.
(e) For so long as such membership does not conflict with any applicable law or regulation or listing requirement of Nasdaq or other
securities exchange on which the Common Stock is listed for trading (as determined in good faith by the Board), the Purchaser Designee shall be entitled to serve as a member of, or observer to, at such Purchaser Designees election, committees
of the Board.
(f) Schuler may, and Schuler may request the Purchaser Designee to, as the case may be, resign, at any time with or
without cause. Any vacancy caused by the resignation of the Purchaser Designee shall only be filled with another Purchaser Designee. Any vacancy created by any removal of the Purchaser Designee or an election of Schuler to defer appointing the
Purchaser Designee shall also only be filled with another Purchaser Designee. The Company shall not take any action to remove the Purchaser Designee or fill a vacancy reserved for the Purchaser Designee in each case without the consent of Schuler
unless and until Schuler is no longer entitled to the Purchaser Designee in accordance with Section 2(c) above.
(g) In
addition to any other indemnification rights the Purchaser Designee has pursuant to the Transaction Documents and the Companys Certificate of Incorporation and Bylaws, the Purchaser Designee that serves on the Board shall have the right to
enter into, and the Company agrees to enter into, an indemnification agreement, in a form reasonably satisfactory to the Purchaser Designee, concurrent with such Purchaser Designee becoming a member of the Board. The Company shall maintain director
and officer insurance covering the Purchaser Designee on the same terms and with the same amount of coverage as is provided to other members of the Board. The Company shall reimburse the reasonable expenses
6
incurred by the Purchaser Designee in connection with attending (whether in person or telephonically) all meetings of the Board or committees thereof or other Company related meetings to the same
extent as all other members of the Board are reimbursed for such expenses (or, in case any such expense reimbursement policy shall apply only to non-employee directors, to the same extent as all other non-employee directors). The Purchaser Designee
shall be entitled to the same compensation for service on the Board, including, without limitation, cash fees, stock options, deferred share units, restricted stock and other equity and equity-related awards, as is provided to other non-employee
directors.
(h) The Company and the Purchasers shall take or cause to be taken all lawful action necessary to ensure at all times as of
and following the Closing Date that the Companys Certificate of Incorporation and Bylaws are not inconsistent with the provisions of this Agreement and the Transaction Documents or the transactions contemplated hereby or thereby.
3. Registration Rights.
3.1 Shelf Registration.
(a) Registration Statements. On November 8, 2013, the Company prepared and filed with the SEC a Registration Statement on Form
S-3 (No. 333-192216), for an offering to be made on a continuous basis pursuant to Rule 415 under the Securities Act (the Initial Shelf Registration Statement) of the Initially Registered Securities. On or prior to May 8,
2015, the Company shall prepare and file with the SEC an additional Registration Statement on Form S-3 (or, if Form S-3 is not then available to the Company, on such form of registration statement as is then available to effect a registration for
resale of the Exchange Registrable Securities) for an offering of the Exchange Registrable Securities (which shall include the number of unsold Initially Registered Securities, which may be deregistered from the Initial Shelf Registration Statement
upon the effectiveness of such additional Registration Statement) to be made on a continuous basis pursuant to Rule 415 under the Securities Act (the Exchange Additional Shelf Registration Statement). Promptly following the
Requisite Stockholder Approval, the Company shall prepare and file with the SEC an additional Registration Statement on Form S-3 (or, if Form S-3 is not available to the Company, on such form of registration statement as is then available to effect
a registration for resale of the Registrable Securities) for an offering of all Registrable Securities (which shall include the number of unsold Initially Registered Securities and Exchange Registrable Securities, each of which may be deregistered
from the Exchange Additional Shelf Registration Statement upon the effectiveness of such additional Registration Statement) to be made on a continuous basis pursuant to Rule 415 under the Securities Act (together with the Exchange Additional Shelf
Registration Statement, the Additional Shelf Registration Statements). The Additional Shelf Registration Statement(s) shall include the aggregate amount of Registrable Securities, as applicable, to be registered therein and the
intended methods of distribution thereof, subject to the limitations of Form S-3. To the extent the rules and regulations of the Commission do not permit the Additional Shelf Registration Statement(s) to include all of the Registrable Securities, as
applicable, the Company shall use its best efforts to register the maximum amount permitted by the Commission and those Registrable Securities required to be omitted from such Additional Shelf Registration Statement(s) shall be determined in the
sole discretion of the Principal Purchasers.
7
(b) Effectiveness.
(i) The Company shall use reasonable best efforts to have the Additional Shelf Registration Statement(s) declared effective as soon as
practicable following the respective filing dates thereof. The Company shall notify the Purchasers by facsimile or e-mail as promptly as practicable, and in any event, within 24 hours, after any Registration Statement is declared effective and shall
simultaneously provide the Purchasers with copies of any related Prospectus to be used in connection with the sale or other disposition of the securities covered thereby.
(ii) For not more than 20 consecutive days or for a total of not more than 45 days in any 12-month period, the Company may suspend the use of
any Prospectus included in any Registration Statement contemplated by this Section 3 in the event that the Company determines in good faith that such suspension is necessary to (A) delay the disclosure of material non-public
information concerning the Company, the disclosure of which at the time is not, in the good faith opinion of the Company, in the best interests of the Company or (B) amend or supplement the affected Registration Statement or the related
Prospectus so that such Registration Statement or Prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the case of the
Prospectus in light of the circumstances under which they were made, not misleading (an Allowed Delay); provided, that the Company shall promptly (a) notify each Purchaser holding any Registrable Securities registered
under such Registration Statement in writing of the commencement of and the reasons for an Allowed Delay, but shall not (without the prior written consent of such Purchaser) disclose to such Purchaser any material non-public information giving rise
to an Allowed Delay, (b) advise the Purchasers holding any Registrable Securities registered under such Registration Statement in writing to cease all sales under the Registration Statement until the end of the Allowed Delay and (c) use
commercially reasonable efforts to terminate an Allowed Delay as promptly as practicable.
(c) Shelf Take-Downs. An underwritten
offering or sale of Registrable Securities pursuant to the Initial Shelf Registration Statement and/or the Additional Shelf Registration Statement(s) (a Shelf Take-Down) may be initiated by a Principal Purchaser who is a
Participating Holder (an Initiating Shelf Take-Down Holder). Upon written request to the Company, the Company shall amend or supplement the Initial Shelf Registration Statement and/or the Additional Shelf Registration Statement(s)
for such purpose as soon as practicable. The Company shall send to each Participating Holder in the Initial Shelf Registration Statement and/or the Additional Shelf Registration Statement(s) written notice of such Shelf Take-Down and, if within 5
days after the date of such notice, any such Participating Holder shall so request in writing, the Company shall include in such Shelf Take-Down all or any part of the Registrable Securities such Participating Holder requests to be included, subject
to Section 3.6(a)(ii), it being understood the Company shall not be responsible for any underwriting discounts or commissions in connection with any Shelf Take Down.
8
3.2 Piggyback Registrations. If the Company determines to prepare and file with the SEC a
Registration Statement relating to an offering for its own account or the account of others of any of its equity securities at any time prior to March 11, 2020 or until such earlier date that no Registrable Securities are outstanding, other
than on Form S-4 or Form S-8 (each as promulgated under the Securities Act) or their then equivalents relating to equity securities to be issued solely in connection with any acquisition of any entity or business or equity securities issuable in
connection with stock option or other employee benefit plans, then the Company shall send to each Holder written notice of such determination and, if within 15 days after the date of such notice, any such Holder shall so request in writing, the
Company shall include in such Registration Statement all or any part of the Registrable Securities such Holder requests to be registered, subject to Section 3.6(b)(ii).
3.3 Expenses. All expenses incident to the Companys performance of or compliance with this Agreement shall be paid by the
Company, other than as set forth in the last sentence of this Section 3.3, including (i) all registration and filing fees, and any other fees and expenses associated with filings required to be made with the SEC, FINRA or any other
regulatory authority and, if applicable, the fees and expenses of any qualified independent underwriter as such term is defined in NASD Rule 2720 (or any successor provision) and of its counsel, (ii) all fees and expenses in
connection with compliance with any securities or Blue Sky laws (including fees and disbursements of counsel for the underwriters in connection with Blue Sky qualifications of the Registrable Securities), (iii) all
printing, duplicating, word processing, messenger, telephone, facsimile and delivery expenses (including expenses of printing certificates for the Registrable Securities in a form eligible for deposit with The Depository Trust Company and of
printing Prospectuses and Free Writing Prospectuses), (iv) all fees and disbursements of counsel for the Company and of all independent certified public accountants of the Company (including the expenses of any special audit and cold comfort
letters required by or incident to such performance), (v) Securities Act liability insurance or similar insurance if the Company so desires or the underwriters so require in accordance with then-customary underwriting practice, (vi) all
fees and expenses incurred in connection with the listing of Registrable Securities on any securities exchange or quotation of the Registrable Securities on any inter-dealer quotation system, (vii) all reasonable fees and disbursements of one
legal counsel for the Participating Holders, as selected by the Principal Purchasers, (viii) any reasonable fees and disbursements of underwriters customarily paid by issuers or sellers of securities, (ix) all fees and expenses of any
special experts or other Persons retained by the Company in connection with any registration, (x) all of the Companys internal expenses (including all salaries and expenses of its officers and employees performing legal or accounting
duties), (xi) all expenses related to the road-show for any underwritten offering, including all travel, meals and lodging and (xii) any other fees and disbursements customarily paid by the issuers of securities. All such
expenses are referred to herein as Registration Expenses. Notwithstanding the foregoing, the Company shall not be required to pay any underwriting discounts and commissions and transfer taxes, if any, attributable to the sale of
Registrable Securities.
3.4 Company Obligations. The Company will use reasonable best efforts to effect the registration of the
Registrable Securities in accordance with the terms hereof, and pursuant thereto the Company will, as expeditiously as possible:
9
(a) prepare the required Registration Statement including all exhibits and financial statements
required under the Securities Act to be filed therewith, and before filing a Registration Statement, Prospectus or any Free Writing Prospectus, or any amendments or supplements thereto, (x) furnish to the underwriters, if any, and the
Participating Holders, if any, copies of all documents prepared to be filed, which documents shall be subject to the review of such underwriters and the Participating Holders and their respective counsel and (y) except in the case of a
registration under Section 3.2, not file any Registration Statement or Prospectus or amendments or supplements thereto to which any Participating Holders or the underwriters, if any, shall reasonably object;
(b) as promptly as practicable file with the SEC a Registration Statement relating to the Registrable Securities including all exhibits and
financial statements required by the SEC to be filed therewith, and use its reasonable best efforts to cause such Registration Statement to become effective under the Securities Act;
(c) prepare and file with the SEC such pre- and post-effective amendments to such Registration Statement, supplements to the Prospectus and
such amendments or supplements to any Free Writing Prospectus as may be (y) reasonably requested by any Participating Holder or (z) necessary to keep such Registration effective for the Registration Period, and comply with provisions of
the applicable securities laws with respect to the sale or other disposition of all securities covered by such Registration Statement during such period in accordance with the intended method or methods of disposition by the sellers thereof set
forth in such Registration Statement;
(d) promptly notify the Participating Holders and the managing underwriter or underwriters, if
any, and (if requested) confirm such advice in writing and provide copies of the relevant documents, as soon as reasonably practicable after notice thereof is received by the Company (A) when the applicable Registration Statement or any
amendment thereto has been filed or becomes effective, and when the applicable Prospectus or Free Writing Prospectus or any amendment or supplement thereto has been filed, (B) of any written comments by the SEC or any request by the SEC for
amendments or supplements to such Registration Statement, Prospectus or Free Writing Prospectus or for additional information, (C) of the issuance by the SEC of any stop order suspending the effectiveness of such Registration Statement or any
order by the SEC preventing or suspending the use of any preliminary or final Prospectus or any Free Writing Prospectus or the initiation or threatening of any proceedings for such purposes, (D) if, at any time, the representations and
warranties of the Company in any applicable underwriting agreement cease to be true and correct in all material respects, (E) of the receipt by the Company of any notification with respect to the suspension of the qualification of the
Registrable Securities for offering or sale in any jurisdiction and (F) of the receipt by the Company of any notification with respect to the initiation or threatening of any proceeding for the suspension of the qualification of the Registrable
Securities for offering or sale in any jurisdiction;
(e) promptly notify the Participating Holders and the managing underwriter or
underwriters, if any, when the Company becomes aware of the happening of any event as a result of which the Registration Statement, the Prospectus included in such
10
Registration Statement (as then in effect) or any Free Writing Prospectus contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements
therein (in the case of such Prospectus, any preliminary Prospectus or any Free Writing Prospectus, in light of the circumstances under which they were made) not misleading, when any Free Writing Prospectus includes information that may conflict
with the information contained in the Registration Statement, or, if for any other reason it shall be necessary during such time period to amend or supplement such Registration Statement, Prospectus or Free Writing Prospectus in order to comply with
the Securities Act and, in either case as promptly as reasonably practicable thereafter, prepare and file with the SEC and furnish without charge to the Participating Holders and the managing underwriter or underwriters, if any, an amendment or
supplement to such Registration Statement, Prospectus or Free Writing Prospectus which shall correct such misstatement or omission or effect such compliance;
(f) promptly incorporate in a Prospectus supplement, Free Writing Prospectus or post-effective amendment to the applicable Registration
Statement such information as the managing underwriter or underwriters and the Participating Holders agree should be included therein relating to the plan of distribution with respect to such Registrable Securities, and make all required filings of
such Prospectus supplement, Free Writing Prospectus or post-effective amendment as soon as reasonably practicable after being notified of the matters to be incorporated in such Prospectus supplement, Free Writing Prospectus or post-effective
amendment;
(g) during the Registration Period, furnish to each Participating Holder and each underwriter, if any, without charge, as
many conformed copies as such Participating Holder or underwriter may reasonably request of the applicable Registration Statement and any amendment or post-effective amendment thereto, including financial statements and schedules, all documents
incorporated therein by reference and all exhibits (including those incorporated by reference);
(h) during the Registration Period,
deliver to each Participating Holder and each underwriter, if any, without charge, as many copies of the applicable Prospectus (including each preliminary Prospectus), any Free Writing Prospectus and any amendment or supplement thereto as such
Participating Holder or underwriter may reasonably request (it being understood that the Company consents to the use of such Prospectus, any Free Writing Prospectus and any amendment or supplement thereto by such Participating Holder and the
underwriters, if any, in connection with the offering and sale of the Registrable Securities thereby) and such other documents as such Participating Holder or underwriter may reasonably request in order to facilitate the disposition of the
Registrable Securities by such Participating Holder or underwriter;
(i) on or prior to the date on which the Registration Statement is
declared effective, use its reasonable best efforts to register or qualify, and cooperate with the Participating Holders, the managing underwriter or underwriters, if any, and their respective counsel, in connection with the registration or
qualification of such Registrable Securities for offer and sale under the securities or Blue Sky laws of each state and other jurisdiction of the United States as any Participating Holder or managing underwriter or underwriters, if any,
or
11
their respective counsel reasonably request in writing and do any and all other acts or things reasonably necessary or advisable to keep such registration or qualification in effect for such
period as required by this Agreement, provided that the Company shall not be required to qualify generally to do business in any jurisdiction where it is not then so qualified or to take any action which would subject it to taxation or
general service of process in any such jurisdiction where it is not then so subject;
(j) cooperate with the Participating Holders and
the managing underwriter or underwriters, if any, to facilitate the timely preparation and delivery of certificates representing Registrable Securities to be sold and not bearing any restrictive legends, and enable such Registrable Securities to be
in such denominations and registered in such names as the managing underwriters may request at least two Business Days prior to any sale of Registrable Securities to the underwriters;
(k) use its reasonable best efforts to cause the Registrable Securities covered by the Registration Statement to be registered with or
approved by such other governmental agencies or authorities as may be necessary to enable the seller or sellers thereof or the underwriter or underwriters, if any, to consummate the disposition of such Registrable Securities;
(l) make such representations and warranties to the Participating Holders and the underwriters or agents, if any, in form, substance and
scope as are customarily made by issuers in secondary underwritten public offerings;
(m) enter into such customary agreements (including
underwriting and indemnification agreements) and take all such other actions as the Purchasers or the managing underwriter or underwriters, if any, reasonably request in order to expedite or facilitate the registration and disposition of such
Registrable Securities;
(n) obtain an opinion or opinions from counsel for the Company dated (i) the effective date of the
Registration Statement or (ii), in the event of an underwritten offering, the date of the closing under the underwriting agreement, in customary form, scope and substance, which opinions shall be provided to the Participating Holders or underwriters
and shall be reasonably satisfactory to such Participating Holders or underwriters, as the case may be, and their respective counsel;
(o) in the case of an underwritten offering, obtain for delivery to the Company and the managing underwriter or underwriters, with copies to
the Participating Holders, a cold comfort letter from the Companys independent certified public accountants in customary form and covering such matters of the type customarily covered by cold comfort letters as the managing underwriter or
underwriters reasonably request, dated the date of execution of the underwriting agreement and brought down to the date of the closing under the underwriting agreement;
(p) cooperate with each Participating Holder and each underwriter, if any, participating in the disposition of such Registrable Securities
and their respective counsel in connection with any filings required to be made with FINRA or any other securities regulatory authority;
12
(q) during the Registration Period, use its reasonable best efforts to comply with all
applicable securities laws and make available to its security holders, as soon as reasonably practicable, an earnings statement satisfying the provisions of Section 11(a) of the Securities Act and the rules and regulations promulgated
thereunder;
(r) during the Registration Period, provide and cause to be maintained a transfer agent and registrar for all Registrable
Securities covered by the applicable Registration Statement from and after a date not later than the effective date of such Registration Statement;
(s) use its reasonable best efforts to cause all Registrable Securities covered by the Registration Statement to be listed on each securities
exchange on which any of the Common Stock is then listed or quoted and on each inter-dealer quotation system on which any of the Common Stock is then quoted;
(t) during the Registration Period, make available, during normal business hours, for inspection and review by the Purchasers, advisors to
and representatives of the Purchasers (who may or may not be affiliated with the Purchasers and who are reasonably acceptable to the Company), all financial and other records, all SEC Reports (as defined in the Securities Purchase Agreement) and
other filings with the SEC, and all other corporate documents and properties of the Company as may be reasonably necessary for the purpose of such review, and cause the Companys officers, directors and employees, within a reasonable time
period, to supply all such information reasonably requested by the Purchasers or any such representative, advisor or underwriter in connection with such Registration Statement (including, without limitation, in response to all questions and other
inquiries reasonably made or submitted by any of them), prior to and from time to time after the filing and effectiveness of the Registration Statement for the sole purpose of enabling the Purchasers and such representatives, advisors and
underwriters and their respective accountants and attorneys to conduct initial and ongoing due diligence with respect to the Company and the accuracy of such Registration Statement; and
(u) with a view to making available to the Purchasers the benefits of Rule 144 (or its successor rule) and any other rule or regulation of
the SEC that may at any time permit the Purchasers to sell shares of Common Stock to the public without registration: (i) make and keep public information available, as those terms are understood and defined in Rule 144, until the earlier of
(A) the date as all of the Registrable Securities may be sold without restriction by the holders thereof pursuant to Rule 144 or any other rule of similar effect or (B) such date as all of the Registrable Securities shall have been resold;
(ii) file with the SEC in a timely manner all reports and other documents required of the Company under the Exchange Act; and (iii) furnish to each Purchaser upon request, as long as such Purchaser owns any Registrable Securities,
(A) a written statement by the Company that it has complied with the reporting requirements of the Exchange Act, (B) a copy of the Companys most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q, and (C) such
other information as may be reasonably requested in order to avail such Purchaser of any rule or regulation of the SEC that permits the selling of any such Registrable Securities without registration.
13
3.5 Obligations of the Purchasers.
(a) Each Purchaser shall furnish in writing to the Company such information regarding itself, the Registrable Securities held by it and the
intended method of disposition of the Registrable Securities held by it, as shall be reasonably required to effect the registration of such Registrable Securities and shall execute such documents in connection with such registration as the Company
may reasonably request. At least five Business Days prior to the first anticipated filing date of any Registration Statement, the Company shall notify each Purchaser of the information the Company requires from such Purchaser if such Purchaser
elects to have any of its Registrable Securities included in the Registration Statement. A Purchaser shall provide such information to the Company at least two Business Days prior to the first anticipated filing date of such Registration Statement
if such Purchaser elects to have any of its Registrable Securities included in the Registration Statement.
(b) Each Purchaser, by its
acceptance of the Registrable Securities agrees to cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing of a Registration Statement hereunder, unless such Purchaser has notified the Company
in writing of its election to exclude all of its Registrable Securities from such Registration Statement.
(c) Each Purchaser agrees
that, upon receipt of any notice from the Company of either (i) the commencement of an Allowed Delay pursuant to Section 3.1(b)(ii) or (ii) the happening of an event pursuant to Section 3.4(d)(C)-(F) or
Section 3.4(e) hereof, such Purchaser will immediately discontinue disposition of Registrable Securities pursuant to the Registration Statement covering such Registrable Securities, until the Purchaser is advised by the Company that such
dispositions may again be made.
(d) At the end of the Registration Period, each Purchaser shall discontinue sales of Registrable
Securities pursuant to any Registration Statement upon receipt of notice from the Company of its intention to remove from registration the Registrable Securities covered by any such Registration Statement which remain unsold, and each Purchaser
shall notify the Company of the number of Registrable Securities so registered which remain unsold promptly upon receipt of such notice from the Company.
3.6 Underwriting.
(a)
Shelf Registrations.
(i) If the Initiating Shelf Take-Down Holder so requests, an offering of Registrable Securities shall be in
the form of an underwritten offering, and such Initiating Shelf Take-Down Holder shall have the right to select the managing underwriter or underwriters to administer the offering. In the case of an underwritten offering under
Section 3.1, the price, underwriting discount and other financial terms for the Registrable Securities shall be determined by the Initiating Shelf Take-Down Holder.
14
(ii) If the managing underwriter or underwriters of a proposed underwritten offering of the
Registrable Securities included in a Shelf Take-Down initiated by an Initiating Shelf Take-Down Holder advise the Board in writing that, in its or their opinion, the number of securities requested to be included in such Shelf Take-Down exceeds the
number which can be sold in such offering without being likely to have a significant adverse effect on the price, timing or distribution of the securities offered or the market for the securities offered, the securities to be included in such Shelf
Take-Down (i) first, shall be allocated pro rata among the Participating Holders that have requested to participate in such Shelf Take-Down based on the relative number of Registrable Securities requested by each Participating
Holder to be included in such Shelf Take-Down and (ii) second, and only if all the securities referred to in clause (i) have been included in such Shelf Take-Down, the number of securities that the Company proposes to include in
such Shelf Take-Down that, in the opinion of the managing underwriter or underwriters, can be sold without having such adverse effect.
(iii) If requested by the underwriters for any underwritten offering requested by an Initiating Shelf Take-Down Holder under
Section 3.1, the Company shall enter into an underwriting agreement with such underwriters for such offering, such agreement to be reasonably satisfactory in substance and form to the Company, the Initiating Shelf Take-Down Holder and
the underwriters, and to contain such representations and warranties by the Company and such other terms as are generally prevailing in agreements of that type, including customary indemnities.
(b) Piggyback Registrations.
(i) If the Company proposes to register any of its securities under the Securities Act as contemplated by Section 3.2 and such
securities are to be distributed in an underwritten offering through one or more underwriters, the Company shall, if requested by any Holders pursuant to Section 3.2, use its reasonable best efforts to arrange for such underwriters to
include on the same terms and conditions that apply to the other sellers in such registration all the Registrable Securities to be offered and sold by such Holders among the securities of the Company to be distributed by such underwriters in such
registration.
(ii) If the managing underwriter or underwriters of any proposed underwritten offering including Registrable Securities
pursuant to Section 3.2 informs the Company and each Participating Holder that, in its or their opinion, the number of securities which the Participating Holders intend to include in such offering exceeds the number which can be sold in
such offering without being likely to have a significant adverse effect on the price, timing or distribution of the securities offered or the market for the securities offered, then the securities to be included in such registration shall be
(i) first, 100% of the securities that the Company and (ii) second, and only if all the securities referred to in clause (i) have been included, the number of Registrable Securities that, in the opinion of such managing
underwriter or underwriters, can be sold without having such adverse effect in such registration, which such number shall be allocated pro rata among the Participating Holders that have requested to participate in such registration based on
the relative number of Registrable Securities requested by each Participating Holder to be included in such underwritten offering.
15
(c) Participation in Underwritten Registrations. Subject to the provisions of
Section 3.6(a)(ii) and Section 3.6(b)(ii) above, no Person may participate in any underwritten offering hereunder unless such Person (i) agrees to sell such Persons securities on the basis provided in any
underwriting arrangements approved by the Persons entitled to approve such arrangements and (ii) completes and executes all questionnaires, powers of attorney, indemnities, underwriting agreements and other documents required under the terms of
such underwriting arrangements and all applicable securities laws. The Participating Holders shall be parties to such underwriting agreement, which underwriting agreement shall (i) contain such representations and warranties by, and the other
agreements on the part of, the Company to and for the benefit of such Participating Holders as are customarily made by issuers to selling stockholders in secondary underwritten public offerings and (ii) provide conditions precedent to the
obligations of such Participating Holders as are customarily provided with respect to selling stockholders in secondary underwritten public offerings. Any such Participating Holder shall not be required to make any representations or warranties to
or agreements with the Company or the underwriters in connection with such underwriting agreement other than representations, warranties or agreements as are customarily made by selling stockholders in secondary underwritten public offerings
regarding such Participating Holder, such Participating Holders title to the Registrable Securities, such Participating Holders authority to sell the Registrable Securities, such Participating Holders intended method of
distribution, absence of liens with respect to the Registrable Securities, enforceability of the applicable underwriting agreement as against such Participating Holder, receipt of all consents and approvals with respect to the entry into such
underwriting agreement and the sale of such Registrable Securities and any other representations required to be made by such Participating Holder under applicable law, rule or regulation, and the aggregate amount of the liability of such
Participating Holder in connection with such underwriting agreement shall not exceed such Participating Holders net proceeds from such underwritten offering.
(d) Clear Market. With respect to any underwritten offerings of Registrable Securities by the Holders, the Company agrees not to, and
shall not be obligated to, effect any public sale or distribution, or to file any Registration Statement covering any of its equity securities or any securities convertible into or exchangeable or exercisable for such securities, during the period
not to exceed ten days prior and sixty days following the effective date of such offering (or such lesser period that the managing underwriters in any underwritten offering permit). Notwithstanding the foregoing, the Company may effect (x) the
registration of (A) equity securities and/or options or other rights in respect thereof solely registered on Form S-4 or Form S-8 (or successor form) or (B) shares of equity securities and/or options or other rights in respect thereof to
be offered to directors, employees, consultants, customers, lenders or vendors of the Company or its Subsidiaries or in connection with dividend reinvestment plans and (y) the Rights Offering.
3.7 Indemnification.
(a) Indemnification by the Company. The Company will indemnify and hold harmless each Purchaser and its officers, directors, members,
employees and agents, successors and assigns, and each other person, if any, who controls such Purchaser within the meaning of the Securities Act, against any losses, claims, damages or liabilities, joint or several,
16
to which they may become subject under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon:
(i) any untrue statement or alleged untrue statement of any material fact contained in any Registration Statement, any preliminary Prospectus or final Prospectus, or any amendment or supplement thereof or any omission or alleged omission to
state a material fact required to be stated therein or necessary to make the statements therein not misleading, in light of the circumstances in which they were made; (ii) any Blue Sky application or other document executed by the
Company specifically for that purpose or based upon written information furnished by the Company filed in any state or other jurisdiction in order to qualify any or all of the Registrable Securities under the securities laws thereof (any such
application, document or information herein called a Blue Sky Application); (iii) the omission or alleged omission to state in a Blue Sky Application a material fact required to be stated therein or necessary to make the
statements therein not misleading, in light of the circumstances in which they were made; (iv) any violation by the Company or its agents of any rule or regulation promulgated under the Securities Act applicable to the Company or its agents and
relating to action or inaction required of the Company in connection with such registration; or (v) any failure to register or qualify the Registrable Securities included in any such Registration Statement in any state where the Company or its
agents has affirmatively undertaken or agreed in writing that the Company will undertake such registration or qualification on a Purchasers behalf and will reimburse such Purchaser, and each such officer, director or member and each such
controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the Company will not be liable in
any such case if and to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission so made in conformity with information furnished by such
Purchaser or any such controlling person in writing specifically for use in such Registration Statement or Prospectus.
(b)
Indemnification by the Purchasers. Each Purchaser agrees, severally but not jointly, to indemnify and hold harmless, to the fullest extent permitted by law, the Company, its directors, officers, employees, stockholders and each person who
controls the Company (within the meaning of the Securities Act) against any losses, claims, damages, liabilities and expense (including reasonable attorney fees) resulting from any untrue statement or alleged untrue statement of a material fact or
any omission or alleged omission of a material fact required to be stated in a Registration Statement or Prospectus or preliminary Prospectus or amendment or supplement thereto or necessary to make the statements therein not misleading, in light of
the circumstances in which they were made, to the extent, but only to the extent that such untrue statement or alleged untrue statement or omission or alleged omission is contained in any information furnished in writing by such Purchaser to the
Company specifically for inclusion in such Registration Statement or Prospectus or amendment or supplement thereto. In no event shall the liability of a Purchaser be greater in amount than the dollar amount of the proceeds (net of all expenses paid
by such Purchaser in connection with any claim relating to this Section 3 and the amount of any damages such Purchaser has otherwise been required to pay by reason of such untrue statement or omission) received by such Purchaser upon the
sale of the Registrable Securities included in a Registration Statement giving rise to such indemnification obligation.
17
(c) Conduct of Indemnification Proceedings. Any Person entitled to indemnification
hereunder shall (i) give prompt notice to the indemnifying party of any claim with respect to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory
to the indemnified party (provided, however, that such indemnified party shall, at the expense of the indemnifying party, be entitled to counsel of its own choosing to monitor such defense); provided that, subject to the
preceding sentence, any Person entitled to indemnification hereunder shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such Person
unless (a) the indemnifying party has agreed to pay such fees or expenses, or (b) the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such person or (c) in the
reasonable judgment of any such Person, based upon written advice of its counsel, a conflict of interest exists between such person and the indemnifying party with respect to such claims (in which case, if the Person notifies the indemnifying party
in writing that such Person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such Person); and provided,
further, that the failure of any indemnified party to give notice as provided herein shall not relieve the indemnifying party of its obligations hereunder, except to the extent that such failure to give notice shall materially adversely
affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one
separate firm of attorneys at any time for all such indemnified parties. No indemnifying party will, except with the consent of the indemnified party, consent to entry of any judgment or enter into any settlement that does not include as an
unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect of such claim or litigation.
(d) Contribution. If for any reason the indemnification provided for in the preceding paragraphs (a) and (b) is unavailable
to an indemnified party or insufficient to hold it harmless, other than as expressly specified therein, then the indemnifying party shall contribute to the amount paid or payable by the indemnified party as a result of such loss, claim, damage or
liability in such proportion as is appropriate to reflect the relative fault of the indemnified party and the indemnifying party, as well as any other relevant equitable considerations. No Person guilty of fraudulent misrepresentation within the
meaning of Section 11(f) of the Securities Act shall be entitled to contribution from any Person not guilty of such fraudulent misrepresentation. In no event shall the contribution obligation of a holder of Registrable Securities be greater in
amount than the dollar amount of the proceeds (net of all expenses paid by such holder in connection with any claim relating to this Section 3 and the amount of any damages such holder has otherwise been required to pay by reason of such
untrue or alleged untrue statement or omission or alleged omission) received by it upon the sale of the Registrable Securities giving rise to such contribution obligation.
4. Miscellaneous.
4.1
Governing Law; Jurisdiction. This Agreement shall be governed by, and construed in accordance with, the internal laws of the State of Delaware without regard to the
18
choice of law principles thereof. Each of the parties hereto irrevocably submits to the exclusive jurisdiction of the state and federal courts located in the State of Delaware for the purpose of
any suit, action, proceeding or judgment relating to or arising out of this Agreement and the transactions contemplated hereby. Service of process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in
the world by the same methods as are specified for the giving of notices under this Agreement. Each of the parties hereto irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in
such court. Each party hereto irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court
has been brought in an inconvenient forum.
4.2 Successors and Assigns. Except as otherwise expressly provided herein, the
provisions hereof shall inure to the benefit of, and be binding upon, the successor and assigns of the parties hereto (other than the rights of any Holder under Sections 2 or 3 hereof, which shall not be assignable and shall not inure
to the benefit of any successor or assign of a Holder). The Company may not assign its rights or obligations hereunder except with the prior written consent of each Holder. Each Holder may assign its respective rights hereunder in the manner and to
the Persons permitted under the most recent purchase or exchange agreement (or the terms of the securities issued thereunder) pursuant to which it acquired securities, except as specified above.
4.3 Entire Agreement; Amendment. This Agreement and the other Transaction Documents constitute the full and entire understanding and
agreement between the parties with regard to the subjects hereof and thereof. Any previous agreements among the parties relative to the specific subject matter hereof are superseded by this Agreement. Any term of this Agreement may be amended and
the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company, and the Principal Purchasers; provided,
however, that any such amendment that adversely affects any Holder in a manner that does not apply uniformly to all Holders shall require the written consent of such adversely affected Holder. Any amendment or waiver effected in accordance
with this Section 4.3 shall be binding upon each Holder, each future Holder, and the Company.
4.4 Notices. All notices
and other communications provided for or permitted hereunder to be sent to each Purchaser shall be made in the manner specified within the most recent purchase or exchange agreement pursuant to which such Purchaser acquired Securities or such other
address subsequently provided by such Purchaser to the Company in writing.
4.5 Severability. If any term, provision, covenant or
restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and
shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such
term, provision, covenant or restriction. It is hereby stipulated and declared to be the
19
intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal,
void or unenforceable.
4.6 Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and
shall not be deemed to limit or affect any of the provisions hereof.
4.7 Counterparts. This Agreement may be executed in two or
more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties
need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a .pdf format data file, such signature shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or .pdf signature page were an original thereof.
4.8 Delays or Omissions. It is agreed that no delay or omission to exercise any right, power or remedy accruing to any party upon any
breach or default of any other party under this Agreement shall impair any such right, power or remedy, nor shall it be construed to be a waiver of any such breach or default, or any acquiescence therein, or of any similar breach or default
thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. It is further agreed that any waiver, permit, consent or approval of any kind or
character of any breach or default under this Agreement, or any waiver of any provisions or conditions of this Agreement must be in writing and shall be effective only to the extent specifically set forth in writing, and that all remedies, either
under this Agreement, by law or otherwise, shall be cumulative and not alternative.
4.9 Consents. Any permission, consent, or
approval of any kind or character under this Agreement shall be in writing and shall be effective only to the extent specifically set forth in such writing.
4.10 SPECIFIC PERFORMANCE. THE PARTIES HERETO AGREE THAT IRREPARABLE DAMAGE WOULD OCCUR IN THE EVENT THAT ANY OF THE PROVISIONS OF THIS
AGREEMENT WERE NOT PERFORMED IN ACCORDANCE WITH ITS SPECIFIC INTENT OR WERE OTHERWISE BREACHED. IT IS ACCORDINGLY AGREED THAT THE PARTIES SHALL BE ENTITLED TO AN INJUNCTION OR INJUNCTIONS, WITHOUT BOND, TO PREVENT OR CURE BREACHES OF THE PROVISIONS
OF THIS AGREEMENT AND TO ENFORCE SPECIFICALLY THE TERMS AND PROVISIONS HEREOF, THIS BEING IN ADDITION TO ANY OTHER REMEDY TO WHICH THEY MAY BE ENTITLED BY LAW OR EQUITY, AND ANY PARTY SUED FOR BREACH OF THIS AGREEMENT EXPRESSLY WAIVES ANY DEFENSE
THAT A REMEDY IN DAMAGES WOULD BE ADEQUATE.
4.11 Construction of Agreement. No provision of this Agreement shall be construed
against either party as the drafter thereof.
20
4.12 Section References. Unless otherwise stated, any reference contained herein to a
Section or subsection refers to the provisions of this Agreement.
4.13 Variations of Pronouns. All pronouns and all variations
thereof shall be deemed to refer to the masculine, feminine, or neuter, singular or plural, as the context in which they are used may require.
[Remainder of Page Intentionally Left Blank]
21
IN WITNESS WHEREOF, the parties have caused this Second Amended and Restated Investor Rights
Agreement to be duly executed and delivered by their proper and duly authorized officers as of the day and year first written above.
|
|
|
HANSEN MEDICAL, INC. |
|
|
By: |
|
/s/ Christopher P. Lowe |
Name: |
|
Christopher P. Lowe |
Title: |
|
Interim Chief Financial Officer |
[Second Amended and
Restated Investor Rights Agreement Signature Page]
|
|
|
SCHULER FAMILY FOUNDATION |
|
|
By: |
|
/s/ Jack W. Schuler |
Name: |
|
Jack W. Schuler |
Title: |
|
Trustee |
[Second Amended and
Restated Investor Rights Agreement Signature Page]
|
|
|
ORACLE PARTNERS, LP |
|
|
By: |
|
/s/ Larry N. Feinberg |
Name: |
|
Larry N. Feinberg |
Title: |
|
Managing Member of General Partner |
[Second Amended and
Restated Investor Rights Agreement Signature Page]
|
|
|
ORACLE TEN FUND MASTER, LP |
|
|
By: |
|
/s/ Larry N. Feinberg |
Name: |
|
Larry N. Feinberg |
Title: |
|
Managing Member of General Partner |
[Second Amended and
Restated Investor Rights Agreement Signature Page]
|
|
|
ORACLE INSTITUTIONAL PARTNERS, LP |
|
|
By: |
|
/s/ Larry N. Feinberg |
Name: |
|
Larry N. Feinberg |
Title: |
|
Managing Member of General Partner |
[Second Amended and
Restated Investor Rights Agreement Signature Page]
|
|
|
FEINBERG FAMILY TRUST |
|
|
By: |
|
/s/ Adam Usdan |
Name: |
|
Adam Usdan |
Title: |
|
Trustee |
[Second Amended and
Restated Investor Rights Agreement Signature Page]
|
MATTHEW STROBECK |
|
/s/ Matthew Strobeck |
Name: Matthew Strobeck |
[Second Amended and
Restated Investor Rights Agreement Signature Page]
|
|
|
BIRCHVIEW FUND LLC |
|
|
By: |
|
/s/ Matthew Strobeck |
Name: |
|
Matthew Strobeck |
Title: |
|
Managing Member |
[Second Amended and
Restated Investor Rights Agreement Signature Page]
|
VAUGHN BRYSON |
|
/s/ Vaughn Bryson |
Name: Vaughn Bryson |
[Second Amended and
Restated Investor Rights Agreement Signature Page]
|
GARO ARMEN |
|
/s/ Garo Armen |
Name: Garo Armen |
[Second Amended and
Restated Investor Rights Agreement Signature Page]
|
|
|
KENNEDY PRIVATE EQUITY, LLC |
|
|
By: |
|
Kennedy Associates LLC, its manager |
|
|
By: |
|
/s/ Lawrence T. Kennedy, Jr. |
Name: |
|
Lawrence T. Kennedy, Jr. |
Title: |
|
Vice President |
[Second Amended and
Restated Investor Rights Agreement Signature Page]
|
|
|
THE JOHN AND CHRISTINE BROWNER FAMILY IRREVOCABLE TRUST |
|
|
By: |
|
/s/ Christine K. Browner |
Name: |
|
Christine K. Browner |
Title: |
|
Trust Advisor |
[Second Amended and
Restated Investor Rights Agreement Signature Page]
|
|
|
CENTRAL PARK ASSOCIATES, LLC |
|
|
By: |
|
/s/ Lawrence T. Kennedy, Jr. |
Name: |
|
Lawrence T. Kennedy, Jr. |
Title: |
|
Managing Member |
[Second Amended and
Restated Investor Rights Agreement Signature Page]
|
|
|
MARTHA K. LORD REVOCABLE TRUST |
|
|
By: |
|
/s/ Martha K. Lord |
Name: |
|
Martha K. Lord |
Title: |
|
Trustee |
[Second Amended and
Restated Investor Rights Agreement Signature Page]
|
|
|
PETER M. KENNEDY REVOCABLE TRUST |
|
|
By: |
|
/s/ Peter M. Kennedy |
Name: |
|
Peter M. Kennedy |
Title: |
|
Trustee |
[Second Amended and
Restated Investor Rights Agreement Signature Page]
|
|
|
DENISON ASSOCIATES, LLC |
|
|
By: |
|
/s/ Peter M. Kennedy |
Name: |
|
Peter M. Kennedy |
Title: |
|
Managing Member |
[Second Amended and
Restated Investor Rights Agreement Signature Page]
|
|
|
FREDERIC HUTCHINS MOLL REVOCABLE TRUST |
|
|
By: |
|
/s/ Frederic H. Moll, M.D. |
Name: |
|
Frederic H. Moll, M.D. |
Title: |
|
Executor |
[Second Amended and
Restated Investor Rights Agreement Signature Page]
SCHEDULE I
EXISTING INVESTORS
1. |
Tino Hans Schuler Trust |
2. |
Tanya Eve Schuler Trust |
3. |
Therese Heidi Schuler Trust |
8. |
William R. Rohn and Mary Jane Rohn Family Trust Dated August 12, 1999 |
9. |
Hykes Family 2013 Irrevocable Trust |
10. |
Stephen L. Newman, M.D. |
11. |
Catherine H. Kennedy Revocable Trust |
12. |
Christine K. Browner Revocable Trust |
13. |
Lawrence T. Kennedy, Jr. Revocable Trust |
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024